biojector
dna
vaccin
prime
n
needl
syring
dna
vaccin
prime
pu
rad
booster
vaccin
pu
rad
booster
vaccin
subject
requir
week
studi
complet
primeboost
regimen
clinic
followup
longterm
followup
one
year
later
week
encourag
allow
hiv
test
longterm
immunolog
evalu
interview
signific
health
chang
howev
subject
may
opt
longterm
contact
occur
telephon
email
mail
interview
primari
endpoint
safeti
primeboost
vaccin
regimen
secondari
endpoint
cellular
immun
respons
week
rd
dna
vaccin
week
rad
booster
neutral
antibodi
titer
week
rad
booster
social
impact
particip
hiv
vaccin
studi
exploratori
analys
includ
assay
cellular
humor
immun
interv
day
week
week
subject
opt
return
longterm
followup
blood
draw
center
diseas
control
prevent
cdc
estim
unit
state
peopl
live
human
immunodefici
viru
hiv
infect
approxim
unawar
infect
worldwid
rate
new
hiv
infect
continu
increas
although
new
acquir
immunodefici
syndrom
aid
diagnos
death
fallen
significantli
develop
countri
sinc
advent
highli
activ
antiretrovir
therapi
haart
develop
world
hivaid
epidem
continu
acceler
global
impact
epidem
stagger
accord
joint
unit
nation
programm
hivaid
world
health
organ
end
million
peopl
estim
live
hivaid
global
total
resid
develop
world
worldwid
estim
million
death
due
hivaid
mani
million
death
result
hiv
infect
sinc
begin
epidem
beyond
human
tragedi
hivaid
cost
epidem
pose
signific
impedi
econom
growth
polit
stabil
mani
countri
develop
countri
segment
us
popul
antihiv
therapi
frequent
beyond
financi
reach
accordingli
effect
lowcost
tool
hiv
prevent
vaccin
urgent
need
bring
hiv
epidem
control
reason
vaccin
research
center
vrc
divis
aid
daid
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
commit
develop
safe
effect
vaccin
prevent
hiv
infect
aid
worldwid
use
multival
vaccin
contain
defin
mixtur
immunogen
number
preval
subtyp
might
feasibl
approach
achiev
broadlyprotect
hiv
vaccin
world
health
organ
unaid
hiv
vaccin
advisori
committe
recommend
candid
hiv
vaccin
design
base
upon
strain
preval
countri
trial
conduct
vaccin
research
center
niaid
nih
world
health
organizationjoint
unit
nation
programm
hivaid
organ
meet
focus
genet
divers
hiv
strategi
develop
vaccin
candid
consensu
reach
gener
multiclad
candid
vaccin
high
intern
scientif
prioriti
approach
foundat
multiclad
design
primeboost
vaccin
regimen
develop
strategi
dna
vaccin
well
adenovir
vector
vaccin
encod
gag
pol
gene
sequenc
clade
b
well
divers
env
gene
clade
b
c
dna
vaccin
also
encod
clade
b
nef
gene
sequenc
clade
b
c
togeth
repres
viral
subtyp
respons
new
hiv
infect
world
combin
modal
regimen
use
deoxyribonucl
acid
dna
vaccin
prime
follow
viral
vector
boost
shown
promis
nonhuman
primat
model
hiv
infect
primeboost
regimen
investig
vaccin
use
phase
studi
evalu
nonhuman
primat
model
show
promis
immunogen
result
summar
protocol
section
seri
previou
preclin
studi
similar
predecessor
vaccin
construct
use
dna
vaccin
rad
page
primeboost
vaccin
regimen
potenti
rais
high
level
immun
respons
nonhuman
primat
model
hiv
infect
publish
exampl
strategi
includ
dna
vaccin
prime
follow
recombin
viral
vector
boost
modifi
vaccinia
ankara
rmva
replicationdefici
recombin
adenovir
vector
vaccin
studi
shown
regimen
attenu
pathogen
shiv
infect
rhesu
macaqu
like
gener
cytotox
lymphocyt
ctl
respons
merck
research
laboratori
publish
preclin
studi
prime
specif
immun
use
adjuvantformul
dna
vaccin
follow
vaccin
boost
gener
level
tcell
immun
respons
compar
naiv
anim
receiv
multipl
high
dose
vaccin
primeboost
regimen
also
shown
promis
preclin
model
prevent
ebola
viru
infect
studi
sponsor
vrc
nih
special
pathogen
branch
cdc
cynomolgu
macaqu
immun
combin
dna
plasmid
mixtur
four
dna
plasmid
encod
glycoprotein
three
ebola
strain
nucleoprotein
one
strain
boost
replicationdefici
adenovir
vector
encod
glycoprotein
resist
lethal
viral
challeng
preclin
studi
suggest
dna
plasmid
vaccin
prime
follow
replicationdefect
adenovir
vector
vaccin
boost
elicit
potent
protect
tcell
immun
respons
primeboost
vaccin
strategi
may
success
human
control
viral
infect
dna
vaccin
administ
vrc
compos
close
circular
deoxyribonucl
acid
dna
plasmid
weight
vaccin
dna
plasmid
vrc
vrc
vrc
design
express
clade
b
gag
pol
nef
respect
dna
plasmid
vrc
vrc
vrc
design
express
env
glycoprotein
clade
clade
b
clade
c
respect
dna
vaccin
design
incorpor
safeti
featur
previou
vrc
vaccin
improv
immunogen
rational
develop
separ
gag
pol
nef
gene
separ
plasmid
rather
one
plasmid
produc
fusion
protein
immunogen
case
vaccin
small
chang
plasmid
expect
enhanc
immunogen
protein
product
produc
vivo
addit
split
gene
separ
plasmid
two
chang
plasmid
construct
chang
promot
incorpor
plasmid
amino
acid
addit
gag
gene
vrc
gag
protein
plasmid
compar
vrc
gagpolnef
fusion
protein
plasmid
preclin
data
indic
separ
gag
pol
nef
plasmid
gener
consist
stronger
immun
respons
gag
pol
nef
immunogen
produc
clade
b
c
env
plasmid
ident
three
env
plasmid
except
promot
known
cmvr
use
rather
cmv
promot
vrc
niaid
nih
collabor
daid
niaid
nih
previous
sponsor
clinic
trial
two
differ
multiclad
dna
vaccin
multiclad
dna
vaccin
multiclad
dna
vaccin
use
studi
tabl
show
statu
may
studi
vaccin
administ
singl
agent
healthi
subject
vaccin
complet
studi
unblind
also
includ
placebo
subject
summari
dose
rang
mg
mg
evalu
dna
vaccin
major
experi
mg
dose
dose
rang
well
toler
phase
studi
uninfect
subject
includ
plan
vaccin
inject
subject
may
uninfect
subject
receiv
one
vaccin
inject
note
experi
clade
b
singl
plasmid
vaccin
dna
vaccin
combin
adjuv
dna
vaccin
hivinfect
subject
shown
studi
togeth
includ
vaccine
date
subject
random
mg
vaccin
inject
subject
random
mg
vaccin
inject
subject
random
mg
vaccin
inject
subject
random
placebo
inject
unblind
final
studi
result
indic
vaccin
inject
well
toler
placebo
inject
vaccin
group
three
advers
event
possibl
relat
vaccin
requir
expedit
report
ind
sponsor
grade
asymptomat
neutropenia
onset
day
vaccin
mg
group
grade
urticaria
onset
day
vaccin
mg
group
grade
maculopapular
rash
onset
day
vaccin
mg
group
resolv
without
sequela
factor
subject
urticaria
includ
concomit
bladder
infect
yeast
infect
multipl
antibiot
maculopapular
rash
result
discontinu
vaccin
schedul
inject
clinic
consist
either
drug
erupt
viral
exanthem
inform
consent
protocol
use
similar
hiv
dna
vaccin
note
risk
neutropenia
maculopapular
rash
urticaria
diari
card
indic
vaccin
inject
well
toler
subject
report
sever
symptom
diari
card
subject
per
group
includ
placebo
recipi
report
least
one
local
symptom
paintend
indur
erythema
point
day
inject
subject
per
group
includ
placebo
recipi
also
report
least
one
system
symptom
day
inject
vaccin
recipi
report
fever
chill
nausea
infrequ
subject
per
dose
group
headach
myalgia
report
per
dose
group
malais
common
system
symptom
occur
vaccine
placebo
recipi
least
day
follow
studi
inject
studi
frequent
record
laboratori
advers
event
includ
asymptomat
hyperglycemia
hypoglycemia
unblind
data
show
placebo
recipi
higher
incid
hyperglycemia
hypoglycemia
data
support
clinic
impress
variat
blood
glucos
unrel
studi
vaccin
preliminari
immunogen
data
week
vrc
studi
sort
treatment
assign
indic
respons
detect
nearli
recipi
dose
level
respons
detect
nearli
half
greatest
respons
frequenc
magnitud
gener
observ
direct
env
immunogen
respons
gag
pol
nef
weak
absent
trend
greater
respons
mg
mg
dose
compar
mg
dose
although
statist
signific
statist
signific
increas
respons
inject
compar
inject
mg
mg
dose
level
although
way
determin
due
inject
simpli
matur
respons
follow
inject
definit
respons
first
detect
mg
mg
dose
time
point
week
second
inject
compar
mg
dose
mg
dose
offer
combin
good
safeti
profil
greater
eas
administr
approxim
equival
cellular
immunogen
local
reaction
pain
andor
tender
inject
site
report
particip
mild
erythema
andor
indur
report
particip
local
reaction
mild
moder
except
one
particip
experienc
episod
sever
inject
site
pain
start
minut
first
vaccin
pain
mild
follow
day
resolv
day
sixti
percent
particip
experienc
least
one
mild
moder
system
symptom
malais
myalgia
headach
nausea
vomit
chill
arthralgia
major
symptom
mild
one
particip
report
sever
migrain
headach
day
inject
male
elev
alanin
aminotransferas
alt
ul
aspart
aminotransferas
ast
ul
creatinin
phosphokinas
cpk
ul
laboratori
clinic
evalu
within
normal
limit
subject
report
feel
well
report
exercis
strenuous
three
time
previou
week
consum
alcohol
previou
even
taken
mg
acetaminophen
codein
four
day
prior
visit
lab
valu
return
normal
limit
within
week
elev
cpk
ast
alt
attribut
exercis
assess
unrel
studi
vaccin
date
hvtn
also
support
find
vrc
mg
dosag
vaccin
well
toler
safe
healthi
volunt
vrc
vrc
first
phase
studi
dna
vaccin
openlabel
studi
enrol
subject
august
octob
fourteen
subject
receiv
intramuscular
inject
mg
dose
vaccin
administ
biojector
one
subject
lost
followup
two
vaccin
last
studi
vaccin
administ
decemb
summari
repres
interim
result
may
subject
report
fever
follow
vaccin
reactogen
none
mild
except
two
subject
report
moder
inject
site
pain
one
subject
report
moder
nausea
malais
advers
event
requir
expedit
report
ind
sponsor
grade
gener
urticaria
subject
report
start
antihistamin
week
first
vaccin
report
time
reason
latex
allergi
screen
rollov
booster
studi
vrc
learn
subject
experienc
gener
urticaria
around
time
second
vaccin
suppli
antihistamin
ran
may
subject
chronic
urticaria
well
control
antihistamin
evalu
ongo
etiolog
unknown
time
chronic
urticaria
assess
possibl
relat
studi
vaccin
date
two
moder
grade
advers
event
possibl
attribut
vaccin
intermitt
dizzi
day
durat
begin
day
second
vaccin
one
subject
subject
receiv
third
vaccin
without
recurr
symptom
asymptomat
hypoglycemia
anoth
subject
first
note
followup
visit
day
third
vaccin
last
safeti
evalu
subject
lost
page
product
protocol
date
novemb
protocol
vrc
version
followup
telephon
one
day
second
vaccin
time
subject
report
side
effect
vaccin
last
studi
visit
subject
project
occur
june
unexpect
local
inject
site
reaction
dna
vaccin
observ
mild
cutan
lesion
cm
diamet
vaccin
site
occur
vaccin
administ
occur
subject
subject
routin
ask
call
experi
unusu
problem
studi
vaccin
vaccin
site
cutan
lesion
alarm
subject
enough
prompt
contact
vrc
clinic
prior
next
regularlyschedul
visit
retrospect
three
subject
report
experienc
skin
lesion
start
small
papul
vesicl
within
day
vaccin
day
papul
vesicl
unroof
scab
form
surround
mild
erythema
mild
indur
scab
came
skin
heal
without
treatment
none
cutan
lesion
associ
pustular
exud
fever
rash
urticaria
appear
either
local
infect
allerg
reaction
first
three
cutan
lesion
discov
first
postvaccin
clinic
visit
day
day
time
larg
resolv
fourth
cutan
lesion
examin
clinic
still
activ
stage
biopsi
postvaccin
day
biopsi
demonstr
microscop
subcutan
dermal
perivascular
lymphocyt
infiltr
infiltr
compos
almost
exclus
posit
cell
includ
rare
eosinophil
present
rare
giant
cell
note
process
appear
primarili
subcutan
dermal
respons
vaccin
cutan
manifest
reason
reaction
seen
vrc
studi
evalu
dna
vaccin
deliv
intramuscularli
biojector
known
whether
reaction
correl
strength
vaccineinduc
immun
respons
also
yet
known
eight
subject
remain
followup
vaccineinduc
posit
hiv
elisa
commerci
test
one
timepoint
includ
three
subject
cutan
lesion
preliminari
immunogen
data
vrc
dna
suggest
envspecif
cell
respons
similar
seen
vrc
dna
gagand
nefspecif
respons
also
present
rollov
protocol
vrc
offer
will
elig
vrc
subject
option
receiv
adenovir
vector
boost
pu
particl
unit
dosag
part
initi
evalu
safeti
immunogen
dna
vaccin
primeadenovir
vector
boost
vaccin
regimen
prevent
hiv
infect
protocol
vrc
provid
better
understand
occurr
develop
etiolog
vaccineassoci
skin
lesion
vrc
includ
plan
prospect
obtain
baselin
postvaccin
photo
vaccin
site
subject
consent
also
obtain
skin
biopsi
skin
lesion
option
skin
biopsi
document
whether
histolog
consist
initi
impress
skin
lesion
primarili
immun
process
whether
evid
allerg
infecti
foreign
bodi
local
reaction
recombin
adenovir
vector
product
rad
replicationdefici
combin
vaccin
contain
four
recombin
serotyp
adenovir
vector
vector
contain
gene
sequenc
code
clade
b
gag
pol
well
clade
random
placebocontrol
doubleblind
dose
escal
studi
examin
safeti
toler
immun
respons
follow
singl
inject
dose
pu
pu
pu
group
includ
subject
vaccin
placebo
vrc
initi
juli
studi
complet
enrol
subject
novemb
last
studi
visit
occur
april
niaid
intramur
data
safeti
monitor
board
dsmb
review
preliminari
safeti
data
day
followup
prior
dose
escal
blind
data
indic
vaccin
appear
safe
healthi
subject
three
dose
level
evalu
pu
dose
level
associ
less
reactogen
pu
dose
level
pu
dose
group
local
system
paramet
record
diari
card
none
mild
sever
none
subject
experienc
fever
pu
dose
group
four
subject
report
fever
day
mild
moder
sever
four
subject
fever
also
report
moder
headach
day
three
subject
also
report
least
one
moder
system
paramet
malais
myalgia
chill
two
subject
without
fever
report
least
one
moder
system
symptom
malais
myalgia
nausea
one
subject
pu
dose
group
report
moder
inject
site
pain
inject
site
reactogen
otherwis
none
mild
april
one
grade
potenti
lifethreaten
three
grade
moder
advers
event
possibl
relat
vaccin
studi
remain
blind
vaccin
vs
placebo
inject
assign
grade
advers
event
seizur
occur
day
studi
inject
healthi
subject
pu
dose
group
histori
singl
seizur
three
year
prior
studi
enrol
follow
review
past
medic
record
test
result
given
histori
prior
seizur
time
event
month
studi
inject
seizur
assess
unrel
studi
agent
grade
advers
event
possibl
relat
studi
agent
includ
asymptomat
neutropenia
note
day
studi
inject
subject
known
sometim
asymptomat
low
neutrophil
count
prior
enrol
diarrhea
durat
one
day
differ
subject
third
day
studi
inject
steatohepat
fatti
liver
diagnos
extens
evalu
identifi
caus
persist
grade
alt
alanin
aminotransferas
elev
note
start
day
studi
vaccin
clinic
asymptomat
subject
hepatolog
consult
report
impress
condit
like
exist
prior
studi
enrol
contribut
factor
persist
grade
alt
may
alcohol
consumpt
page
product
protocol
date
novemb
protocol
vrc
version
recent
weight
gain
diagnosi
steatohepat
overal
consid
grade
condit
liver
function
test
remain
grade
sever
month
normal
rang
last
studi
visit
repeat
ultrasound
show
fatti
liver
still
present
vrc
studi
propos
use
pu
pu
dose
booster
vaccin
although
reactogen
observ
pu
dose
appear
welltoler
dose
analgesicantipyret
nonprescript
medic
may
self
administ
relief
shortterm
symptom
protocolspecifi
interim
immunogen
analysi
progress
compar
placebo
three
dosag
group
blind
immunogen
data
suggest
dose
effect
increas
immun
respons
higher
dose
number
subject
vaccineinduc
elisa
studi
week
commerci
hivantibodi
assay
increas
pu
group
pu
group
pu
group
among
subject
two
placebo
ten
vaccin
recipi
per
group
preliminari
immunogen
data
vrc
suggest
major
vaccine
develop
env
gagand
polspecif
cell
respons
vrc
one
first
two
studi
primeboost
regimen
earli
stage
develop
rad
booster
vaccin
import
continu
evalu
differ
dosag
continu
gather
data
doserel
immunogen
reactogen
hvtn
second
phase
studi
rad
vaccin
singl
agent
uninfect
adult
subject
blind
dose
escal
studi
submit
bbind
decemb
open
accrual
april
design
enrol
two
group
subject
low
titer
random
rad
placebo
ratio
first
group
vaccine
receiv
pu
rad
second
group
receiv
pu
rad
hvtn
hvtn
bbind
first
phase
studi
administ
adenovir
vector
vaccin
booster
vaccin
blind
phase
studi
singl
boost
pu
placebo
administ
particip
activ
placebo
complet
inject
regimen
placebo
hvtn
rad
boost
given
interv
month
subject
first
inject
hvtn
first
particip
enrol
novemb
april
last
enrol
studi
inject
complet
may
still
blind
reactogen
result
indic
local
pain
andor
tender
report
particip
maxim
sever
moder
report
particip
erythema
andor
indur
greater
cm
report
particip
report
erythema
andor
indur
cm
system
reactogen
exceed
moder
report
mild
symptom
report
moder
symptom
commonli
report
mild
symptom
malais
andor
fatigu
particip
myalgia
particip
headach
particip
commonli
report
moder
symptom
headach
particip
malais
andor
fatigu
particip
myalgia
particip
six
particip
report
grade
fever
none
exceed
c
vrc
vrc
second
phase
studi
rad
booster
vaccin
open
label
studi
design
enrol
subject
complet
three
vaccin
mg
mg
vrc
receiv
pu
rad
booster
vaccin
first
enrol
studi
occur
januari
vrc
vrc
vrc
rollov
subject
togeth
provid
first
safeti
immunogen
data
primeboost
regimen
use
dna
vaccin
prime
vaccin
booster
vaccin
first
booster
inject
subject
prime
dna
vaccin
occur
may
first
vrc
rollov
subject
enrol
vrc
vaccin
research
center
niaid
divis
aid
niaid
evalu
safeti
immunogen
three
investig
dna
plasmid
vaccin
one
investig
dna
plasmid
ebola
vaccin
hiv
vaccin
evalu
extramur
trial
date
dna
vaccin
administ
needleless
deliveri
devic
biojector
manufactur
bioject
corpor
portland
needleless
design
biojector
offer
safeti
advantag
elimin
potenti
accident
needl
stick
illicit
reus
dispos
needl
syring
biojector
disadvantag
expens
use
standard
needl
syring
requir
special
train
use
properli
preclin
studi
nonhuman
primat
describ
section
indic
immunogen
system
safeti
similar
whether
administ
either
needl
syring
biojector
publish
literatur
review
suggest
biojector
associ
inject
site
reactogen
standard
needl
syring
intramuscular
inject
vrc
experi
biojector
occasion
small
mm
cutan
lacer
sometim
associ
subsequ
ecchymos
note
seen
needl
syring
inject
context
futur
intern
phase
ii
phase
iii
studi
import
evalu
whether
dna
inject
administ
needl
syring
equival
immunolog
standpoint
method
administr
may
reduc
cost
ensur
consist
intramuscular
administr
numer
clinic
site
recent
unexpect
observ
mild
skin
lesion
follow
dna
vaccin
inject
vrc
plan
futur
studi
may
also
help
obtain
preliminari
inform
vrc
whether
skin
lesion
observ
follow
im
inject
needl
syring
needl
syring
inject
princip
method
vaccin
administr
worldwid
econom
suitabl
use
variou
environ
howev
develop
countri
commun
risk
concern
associ
convent
needl
syring
use
improp
inject
practic
acknowledg
problem
develop
countri
result
use
nonsteril
needl
syring
transmiss
bloodborn
pathogen
across
patient
popul
literatur
review
report
inject
administ
develop
countri
unsaf
clinic
set
risk
needl
stick
injuri
health
care
worker
burden
proper
needl
dispos
howev
risk
needl
syring
inject
devic
individu
needlefre
inject
system
use
altern
needl
syring
inject
vaccin
needlefre
devic
eject
pressur
fluid
small
orific
nozzl
result
percutan
deliveri
liquid
vaccin
intramuscular
subcutan
intraderm
deposit
foremost
among
advantag
pressur
inject
system
method
vaccin
administr
inher
increas
safeti
afford
needlefre
devic
vaccine
ensur
nonsteril
devic
use
healthcar
worker
elimin
needlestick
injuri
needlefre
inject
system
valuabl
public
health
instrument
develop
countri
mass
vaccin
campaign
may
import
global
event
bioterrorist
attack
anim
human
studi
involv
differ
vaccin
rout
administr
conduct
evalu
safeti
immunogen
needlefre
devic
comparison
standard
needl
syring
dispens
regardless
vaccin
inject
consist
find
sever
studi
increas
local
inflamm
individu
vaccin
via
needlefre
inject
devic
increas
local
reactogen
may
reflect
greater
distribut
inject
minor
tissu
injuri
associ
system
depart
safeti
assess
merck
research
laboratori
publish
studi
includ
comparison
needl
syring
biojector
intramuscular
im
administr
dna
plasmid
vaccin
guinea
pig
six
week
im
inject
either
method
vast
major
dna
plasmid
muscl
hamstr
skin
near
inject
site
skin
show
higher
copi
count
muscl
low
level
dna
plasmid
also
detect
drain
lymph
node
earli
timepoint
day
low
system
exposur
could
also
detect
biojector
deliveri
compar
needl
inject
increas
uptak
dna
plasmid
muscl
skin
near
inject
site
well
associ
slightli
dispers
distal
site
neither
method
associ
integr
dna
plasmid
host
cellular
dna
wider
dispers
pattern
inject
observ
needlefre
inject
devic
biojector
result
local
inflammatori
respons
may
also
enhanc
immunogen
increas
antigen
present
recruit
immunecompet
inflammatori
cell
exampl
report
rabbit
immun
biojector
significantli
improv
antibodi
respons
pfcsp
dna
malaria
vaccin
compar
needl
syring
administr
human
studi
also
report
increas
antibodi
respons
follow
use
biojector
devic
studi
evalu
trival
influenza
vaccin
administ
needl
syring
needlefre
jet
injector
either
vitajet
subcutan
biojector
intramuscularli
biojector
group
higher
postvaccin
antibodi
titer
one
three
influenza
antigen
anoth
studi
subject
vaccin
havrix
biojector
signific
increas
antihepat
viru
antibodi
geometr
mean
titer
seroconvers
rate
compar
vaccin
needl
syring
first
human
studi
pfcsp
dna
malaria
vaccin
four
group
studi
subject
sequenti
enrol
receiv
three
inject
intramuscularli
needl
syring
dose
level
rang
mg
per
inject
vaccin
safe
well
toler
deliv
needl
syring
major
subject
develop
antigenspecif
ctl
respons
respons
higher
dose
group
none
subject
detect
antibodi
pfcsp
basi
preclin
evalu
safeti
immunogen
differ
inject
devic
use
administr
differ
inject
devic
evalu
subsequ
human
clinic
trial
three
inject
method
needl
im
biojector
im
biojector
dose
administ
im
administ
intraderm
id
three
group
includ
vaccine
mg
dose
control
subject
schedul
includ
inject
ml
total
volum
week
imid
administr
plan
requir
inject
time
point
advers
event
gener
mild
limit
inject
site
biojector
inject
associ
twice
mani
advers
event
per
inject
howev
studi
subject
prefer
biojector
inject
regardless
method
administr
antipfcspspecif
antibodi
could
detect
human
clinic
trial
sampl
although
antigenspecif
immun
respons
assess
enzymelink
immunospot
elispot
detect
vaccine
experi
dna
vaccin
indic
intramuscular
inject
needl
syring
result
differ
system
safeti
concern
needleless
inject
devic
use
deliv
intramuscularli
import
concern
develop
adenovir
vector
vaccin
effect
preexist
neutral
antibodi
adenovirus
adult
popul
respons
adenovir
vector
vaccin
util
adenovir
vector
vaccin
human
may
limit
high
titer
neutral
ad
antibodi
present
time
vaccin
adenovir
vector
studi
replic
defect
adenoviru
serotyp
fifti
distinct
human
adenoviru
serotyp
defin
worldwid
base
type
specif
neutral
antibodi
assay
caus
varieti
common
infect
includ
respiratori
infect
seroepidemiolog
survey
assess
adenoviru
variou
us
european
popul
suggest
adenoviru
serotyp
ad
common
present
half
children
test
adenoviru
serotyp
antibodi
detect
elisa
one
studi
young
adult
median
age
neutral
titer
excess
data
nonu
popul
suggest
similar
higher
rate
seropreval
found
popul
target
vaccin
especi
develop
world
studi
human
anim
suggest
preexist
immun
adenoviru
serotyp
may
attenu
immun
respons
adenovir
vector
use
higher
titer
vaccin
andor
primeboost
strategi
may
overcom
potenti
difficulti
effect
preexist
immun
safeti
toler
vector
vaccin
import
concern
data
need
vaccin
experi
review
aid
vaccin
confer
lausann
switzerland
note
subject
receiv
one
investig
hiv
vaccin
fever
common
subject
low
ab
titer
common
x
viral
particl
vp
dose
vaccin
gener
well
toler
preexist
neutral
antibodi
also
note
dampen
immunogen
vector
vaccin
could
overcom
higher
dose
level
therefor
import
evalu
safeti
immunogen
vector
vaccin
set
low
high
preexist
titer
use
differ
dosag
vaccin
vrc
evalu
set
sampl
subject
screen
enrol
investig
vaccin
studi
vrc
clinic
sampl
subject
titer
comparison
sampl
evalu
neutral
assay
use
merck
neutral
assay
use
vrc
studi
vrc
titer
higher
titer
measur
merck
assay
basi
preliminari
popul
data
comparison
known
vaccin
experi
definit
low
antibodi
titer
studi
set
neutral
assay
use
vrc
vrc
design
enrol
approxim
equal
number
subject
high
low
preexist
antibodi
order
gain
preliminari
inform
healthi
adult
whether
safeti
immunogen
respons
vrc
adenovir
vector
vaccin
differ
two
group
subject
much
larger
studi
need
definit
answer
question
howev
exploratori
evalu
help
select
sampl
size
booster
dosag
use
futur
phase
ii
phase
iii
studi
adenovir
vector
vaccin
phase
studi
provid
preliminari
assess
immunogen
primeboost
regimen
employ
intracellular
cytokin
stain
ic
elispot
assay
evalu
ctl
respons
well
assay
evalu
hivspecif
antibodi
respons
ic
assay
base
upon
previous
publish
method
quantit
frequenc
cell
produc
interferongamma
respons
pool
overlap
peptid
repres
hiv
antigen
gag
pol
nef
env
specif
hiv
clade
cladespecif
peptid
also
use
detect
tcell
respons
elispot
assay
modifi
previous
publish
method
antibodi
respons
hivspecif
antibodi
evalu
use
enzymelink
immunosorb
assay
elisa
abil
vaccin
elicit
neutral
antibodi
strain
clade
b
c
evalu
flow
cytometr
assay
measur
capac
sera
block
singl
round
infect
individu
pbmc
preexist
postvaccin
presenc
adenoviru
serotyp
neutral
antibodi
studi
volunt
evalu
frozen
serum
sampl
use
previous
publish
luciferas
transgen
detect
method
assay
may
also
complet
store
sampl
later
date
elucid
immunogen
interest
drug
substanc
six
close
circular
plasmid
dna
macromolecul
vrc
vrc
vrc
vrc
vrc
vrc
combin
equal
concentr
mgml
vrc
encod
clade
b
gag
structur
core
protein
encapsid
viral
rna
exhibit
highli
conserv
domain
vrc
encod
clade
b
polymeras
pol
also
highli
conserv
vrc
encod
clade
b
nef
accessori
protein
vigor
tcell
respons
mount
natur
infect
dna
plasmid
express
pol
modifi
reduc
potenti
toxic
incorpor
chang
region
affect
proteas
revers
transcriptas
integras
activ
two
amino
acid
myristoyl
site
nef
gene
delet
abrog
mhc
class
downregul
nef
protein
modif
made
amino
acid
sequenc
gag
three
plasmid
express
synthet
version
modifi
truncat
envelop
glycoprotein
three
strain
vrc
clade
vrc
clade
b
vrc
clade
c
sequenc
use
creat
dna
plasmid
encod
env
deriv
three
strain
viru
gene
modifi
improv
immunogen
demonstr
mice
monkey
vaccin
potenti
elicit
immun
respons
broad
rang
strain
plasmid
contain
gag
pol
nef
env
complementari
dna
cdna
use
subclon
relev
insert
plasmid
dna
express
vector
use
cmvr
promot
bovin
growth
hormon
polyadenyl
sequenc
plasmid
express
gene
made
synthet
sequenc
design
disrupt
viral
rna
structur
limit
protein
express
use
codon
typic
found
human
therebi
increas
gene
express
translat
enhanc
region
cmv
immedi
earli
region
enhanc
substitut
region
human
tcell
leukemia
viru
type
long
termin
repeat
ltr
optim
gene
express
dna
express
vector
similar
use
candid
vaccin
current
undergo
evalu
clinic
studi
vrc
daidsniaidnih
dna
plasmid
produc
bacteri
cell
cultur
contain
kanamycin
select
medium
case
bacteri
cell
growth
depend
upon
cellular
express
kanamycin
resist
protein
encod
portion
plasmid
dna
follow
growth
bacteri
cell
harbor
plasmid
plasmid
dna
purifi
cellular
compon
gag
plasmid
vrc
nucleotid
pair
length
approxim
molecular
weight
mda
pol
plasmid
vrc
nucleotid
pair
length
approxim
molecular
weight
mda
nef
plasmid
vrc
nucleotid
pair
length
approxim
molecular
weight
mda
clade
b
c
env
plasmid
vrc
nucleotid
length
respect
approxim
molecular
weight
human
somat
cell
therapi
gene
therapi
point
consid
plasmid
dna
vaccin
prevent
infecti
diseas
indic
replicationdefici
combin
vaccin
contain
four
recombin
adenovir
vector
vector
contain
gene
sequenc
code
clade
b
gag
pol
well
clade
clade
b
clade
c
env
protein
vitro
express
vector
produc
immunogen
induc
immun
respons
hiv
envelop
gene
chosen
repres
primari
isol
three
clade
process
construct
four
recombin
adenovir
vector
base
upon
rapid
vector
construct
system
genvec
inc
use
gener
adenovir
vector
express
four
hiv
antigen
b
c
gagpol
b
driven
cytomegaloviru
cmv
immediateearli
promot
manufactur
base
upon
product
proprietari
cell
line
yield
adenovir
vector
replic
defici
vector
purifi
use
cscl
centrifug
product
formul
steril
liquid
inject
dosag
form
intramuscular
inject
adenovir
backbon
chosen
reduc
risk
replicationcompet
adenoviru
rca
gener
clinic
product
backbon
contain
delet
two
essenti
region
well
partial
delet
render
vaccin
product
replicationdefici
gener
rca
would
requir
two
independ
recombin
event
singl
adenoviru
genom
predict
extrem
rare
event
ad
gv
hiv
vector
contain
antigen
open
read
frame
orf
express
cassett
insert
replac
delet
adenoviru
gene
region
delet
adenoviru
region
includ
partial
replac
transcript
inert
spacer
element
enhanc
product
adenovir
vector
cell
line
use
propag
partial
delet
vector
develop
genvec
inc
cell
construct
stabli
transform
cell
human
embryon
kidney
origin
induc
express
cassett
enabl
cell
effici
complement
partial
adenovir
vector
provid
increas
transgen
capac
greatli
reduc
potenti
gener
replicationcompet
adenoviru
particular
clone
given
rise
cell
line
clone
refer
cell
line
refer
cell
deriv
origin
clone
replicationdefici
adenovir
vector
system
use
produc
tnferad
tnfalpha
genebas
product
assay
replicationcompet
adenoviru
perform
final
releas
test
vector
rca
observ
packag
system
manufactur
multipl
genebas
product
vaccin
adenovir
vector
purifi
use
cesium
chlorid
cscl
gradient
centrifug
process
cscl
remov
dialyz
viru
prepar
final
formul
buffer
purifi
adenovir
vector
serv
vector
bank
subsequ
product
four
vaccin
adenovir
vector
vector
bank
test
steril
mycoplasma
adventiti
agent
prior
use
manufactur
clinic
suppli
bulk
plasmid
dna
manufactur
vical
incorpor
san
diego
ca
one
sourc
plasmid
suppli
vrc
use
prepar
master
cell
bank
mcb
plasmid
vical
incorpor
formul
bulk
dna
compon
mgml
phosphat
buffer
salin
pb
six
plasmid
mix
form
final
bulk
vaccin
product
steril
filtrat
fill
oper
conduct
asept
condit
class
environ
vical
incorpor
fill
perform
releas
test
except
express
test
vrc
subcontractor
clinic
trial
materi
test
bulk
plasmid
dna
final
product
vrc
subcontractor
conduct
gene
express
test
fill
product
bulk
vrc
vrc
vrc
vrc
vrc
vrc
upon
confirm
gene
express
vrc
releas
product
final
product
meet
test
specif
releas
use
propos
clinic
studi
multiclad
adenovir
vector
vaccin
product
ratio
adenovir
vector
encod
gagpol
polyprotein
clade
b
env
glycoprotein
clade
b
c
respect
final
product
meet
test
specif
releas
use
propos
clinic
studi
vial
fill
ml
volum
puml
x
puml
ffb
compos
sodium
chlorid
tri
buffer
low
endotoxin
magnesium
monool
tween
water
inject
wfi
preclin
studi
evalu
safeti
immunogen
similar
dna
plasmid
vaccin
alon
follow
rad
vaccin
summar
section
detail
summari
preclin
studi
done
vaccin
avail
investig
brochur
studi
vaccin
glp
biodistribut
studi
sever
vrc
dna
plasmid
vaccin
administ
im
biojector
rabbit
complet
includ
singl
plasmid
vaccin
vaccin
vaccin
singl
plasmid
consist
find
pcr
evalu
timepoint
evalu
rang
studi
day
sd
sd
vector
primarili
local
subcuti
inject
site
magnitud
posit
signal
observ
tissu
earli
timepoint
greatli
diminish
later
time
point
indic
eventu
clearanc
test
articl
glp
biodistribut
studi
complet
adenovir
vector
vaccin
administ
im
needl
syring
rabbit
distribut
profil
consist
test
articl
present
inject
site
subcuti
anim
sd
anim
sd
muscl
anim
sd
spleen
anim
sd
anim
sd
anim
sd
liver
anim
sd
anim
sd
sporad
find
bone
marrow
anim
sd
number
copi
present
posit
tissu
number
anim
posit
tissu
decreas
consider
sd
sd
continu
decreas
sd
sd
object
studi
conduct
glp
gene
logic
inc
gaithersburg
md
assess
potenti
toxic
administ
alon
boost
new
zealand
white
rabbit
vaccin
dna
vaccin
dna
rad
boost
studi
ten
animalsgend
dose
via
intramuscular
inject
dna
vaccin
mg
pb
control
administ
four
time
sd
dosag
divid
intramuscular
inject
space
approxim
inch
apart
mlinject
site
dose
volum
inject
adjust
bodi
weight
time
point
inject
administ
thigh
muscl
use
biojector
needlefre
inject
manag
system
biojector
altern
side
time
point
adenovir
vector
vaccin
pu
ml
volum
diluent
control
inject
ml
volum
divid
two
ml
inject
administr
needl
syring
hind
thigh
muscl
approxim
inch
apart
per
day
dose
sd
inject
administ
altern
side
time
point
ml
volum
administ
regardless
bodi
weight
dna
adenovir
vector
vaccin
respect
control
one
half
anim
sacrif
studi
day
remaind
studi
day
inject
administ
shavedmark
site
site
reshav
remark
need
order
visual
inject
site
paramet
evalu
includ
mortal
clinic
sign
toxic
draiz
local
reactogen
observ
bodi
weight
bodi
weight
chang
food
consumpt
ophthalmolog
examin
clinic
patholog
chemistri
hematolog
coagul
bodi
temperatur
gross
patholog
organ
weight
histopatholog
observ
also
made
motor
function
behavior
studi
made
regard
morbidityclin
observ
ophthalmolog
howev
possibl
primeboost
treatment
effect
seen
bodi
weight
chang
particularli
treat
femal
differ
began
note
earli
studi
day
becam
statist
significantli
differ
control
femal
studi
day
bodi
weight
day
bodi
weight
chang
primeboost
treat
femal
anim
continu
gain
weight
cours
studi
gain
much
weight
control
primeboost
regimen
vaccin
dna
prime
administ
biojector
result
draiz
observ
minim
moder
edema
erythema
increas
frequenc
sever
repeat
dose
observ
also
occur
control
anim
lower
amount
lesser
degre
find
consist
previou
toxicolog
studi
perform
dna
vaccin
alon
boost
adenovir
vector
deliv
needl
syring
inject
increas
frequenc
sever
minim
erythema
andor
edema
treat
anim
draiz
observ
seen
earlier
timepoint
prime
dose
primeboost
anim
histopatholog
find
inflamm
perineur
tissu
surround
sciatic
nerv
near
inject
site
chronic
inflammatori
cell
small
macrophag
lymphocyt
connect
tissu
around
sciatic
nerv
adjac
lymphat
blood
capillari
inflamm
like
result
drainag
distal
inject
site
toward
proxim
lymph
node
inject
site
reaction
decreas
frequenc
sever
recoveri
sacrific
anim
compar
immedi
sacrific
anim
receiv
primeboost
regimen
demonstr
revers
inject
site
reaction
primeboost
treat
anim
fever
seen
treat
male
femal
hour
subsequ
initi
treatment
first
hour
second
adenovir
vector
boost
treat
femal
fever
resolv
hour
initi
treatment
hour
second
treat
femal
adenovir
vector
boost
food
consumpt
also
decreas
compar
control
hour
hour
follow
adenovir
vector
vaccin
resolv
result
differ
bodi
weight
chang
male
femal
inocul
adenovir
vector
alon
treat
male
primeboost
regimen
signific
differ
bodi
weight
chang
treat
femal
note
treat
femal
primeboost
regimen
although
differ
began
prior
exposur
adenovir
vector
discuss
addit
observ
particularli
clinic
chemistri
hematolog
paramet
unclear
relationship
treatment
either
remain
within
histor
normal
rang
speci
even
though
statist
signific
differ
match
control
anim
studi
outsid
normal
rang
differ
control
anim
studi
consist
gender
across
timepoint
none
find
appear
correl
clinic
observ
gross
histopatholog
find
note
find
statist
signific
match
control
studi
elev
triglycerid
day
subsequ
initi
adenovir
vector
boost
treat
male
mean
time
uln
treat
femal
receiv
primeboost
regimen
differ
group
paramet
second
adenovir
vector
boost
either
gender
day
sever
differ
statist
studi
design
compar
immunolog
respons
hiv
vaccin
administ
biojector
needl
syring
anim
also
evalu
train
veterinari
technician
attend
veterinarian
daili
interv
detail
evalu
anim
inject
site
perform
anim
anesthet
wellcharacter
plasmid
dna
althea
technolog
inc
san
diego
ca
express
clade
b
gag
pol
nef
protein
clade
b
c
env
use
immun
plasmid
express
protein
contain
vaccin
group
outbr
cynomolgu
macaqu
monkey
per
group
vaccin
mg
dna
vaccin
ml
inject
quadricep
muscl
use
either
needl
syring
biojector
week
blood
collect
immunolog
assay
twoweek
time
interv
first
week
fourweek
interv
week
elispot
assay
intracellular
cytokin
stain
ic
assay
week
elisa
assay
week
perform
assess
magnitud
vaccineelicit
cellular
humor
immun
respons
elispot
ic
result
similar
monkey
vaccin
biojector
needl
syring
cell
respons
clade
b
gag
pol
nef
env
detect
start
week
group
low
elisa
antibodi
titer
detect
group
anim
signific
differ
monkey
vaccin
biojector
vaccin
needl
syring
anim
show
obviou
advers
clinic
effect
eg
favor
inject
limb
red
abscess
format
indur
either
method
inject
complet
blood
count
perform
monthli
demonstr
valu
gener
within
normal
rang
cynomolgu
macaqu
studi
laboratori
vaccin
biojector
needlesyring
demonstr
signific
differ
specif
antibodi
cellular
respons
cynomolgu
macaqu
inject
deliv
im
rout
result
studi
show
vaccin
deliv
needl
syring
elicit
similar
immunolog
respons
deliv
biojector
needl
syring
biojector
inject
appear
similarli
well
toler
studi
anim
indic
veterinari
observ
complet
blood
count
data
cynomolgu
macaqu
receiv
dna
primerad
boost
immun
elicit
potent
broad
cellular
immun
respons
simultan
viral
antigen
addit
elicit
potent
antibodi
respons
envelop
antigen
gag
antigen
measur
elisa
monkey
receiv
dna
plasmid
vaccin
prime
rad
boost
gener
respons
clade
b
c
env
peptid
pool
six
anim
follow
dna
prime
immun
well
follow
rad
boost
five
six
anim
develop
antibodi
respons
three
envelop
antigen
one
anim
develop
antibodi
respons
clade
c
envelop
antigen
six
monkey
strong
env
antibodi
respons
adenoviru
boost
data
demonstr
clinic
rad
product
immunogen
given
dna
prime
induc
cellular
immun
respons
clade
b
c
env
well
gag
pol
antibodi
respons
clade
b
c
env
well
gag
adenovir
vector
boost
increas
immun
respons
sever
fold
vical
incorpor
perform
releas
test
vaccin
research
center
vrc
test
gene
express
genvec
inc
perform
releas
test
safeti
test
perform
prior
releas
manufactur
lot
adenovir
vector
includ
limit
verif
steril
absenc
contamin
organ
test
addit
viral
safeti
test
perform
master
vector
bank
final
product
includ
limit
test
vivo
vitro
inappar
adventiti
viru
human
tcell
lymphotrop
viru
htlv
htlv
ii
cytomegaloviru
cmv
hepat
b
hepat
c
epsteinbarr
viru
adenoassoci
viru
aav
parvoviru
human
herp
viru
hhv
fluoresc
product
enhanc
revers
transcriptas
fpert
test
retrovirus
addit
safeti
test
level
gene
express
also
quantifi
manufactur
lot
four
adenovir
vector
transfect
western
blot
analysi
evalu
safeti
toler
human
dose
mg
administ
intramuscularli
use
two
differ
method
either
needl
syring
biojector
follow
booster
vaccin
dose
pu
pu
administ
intramuscularli
use
needl
syring
evalu
whether
dose
mg
administ
intramuscularli
use
two
differ
method
either
needl
syring
biojector
show
posit
gag
pol
nef
respons
well
posit
env
respons
assess
hivspecif
peptid
poolstimul
cell
respons
week
third
dose
vaccin
evalu
immunogen
cellular
respons
intracellular
cytokin
stain
elispot
week
booster
vaccin
administ
intramuscularli
pu
pu
needl
syring
subject
titer
previous
receiv
three
inject
evalu
adenoviru
serotyp
neutral
antibodi
titer
week
booster
inject
monitor
social
impact
particip
vaccin
clinic
trial
evalu
immunogen
primeboost
regimen
indic
intracellular
cytokin
stain
elispot
vaccin
antigenspecif
elisa
neutral
assay
immunolog
assay
interv
begin
first
inject
week
booster
inject
phase
random
studi
examin
safeti
toler
immun
respons
schedul
dna
plasmid
vaccin
administ
either
needl
syring
biojector
follow
one
adenovir
vector
rad
booster
vaccin
administ
either
pu
dose
hypothes
regimen
safe
human
administr
elicit
immun
respons
biojector
needlesyring
safe
use
im
inject
dna
vaccin
subject
low
high
preexist
titer
boost
immun
respons
peptid
follow
rad
booster
vaccin
forti
subject
half
high
half
low
titer
random
ratio
receiv
dna
vaccin
either
needl
syring
ns
biojector
also
random
ratio
receiv
booster
vaccin
either
pu
pu
rad
vaccin
safeti
vaccin
regimen
evalu
schedul
studi
visit
studi
subject
report
studi
provid
safeti
data
follow
number
subject
per
vaccin
type
biojector
dna
vaccin
prime
n
needl
syring
dna
vaccin
prime
pu
rad
booster
vaccin
pu
rad
booster
vaccin
specimen
evalu
immunogen
taken
baselin
specifi
time
point
gag
pol
nef
envspecif
immun
respons
assess
cellular
immun
function
assay
humor
immun
assay
studi
subject
requir
week
studi
complet
primeboost
regimen
followup
rad
booster
vaccin
dosag
blind
week
safeti
immunogen
evalu
rad
booster
vaccin
complet
subject
schema
shown
studi
activ
carri
nation
institut
health
neg
volunt
recruit
irbapprov
advertis
screen
vrc
screen
protocol
healthi
volunt
interest
particip
hiv
vaccin
clinic
trial
confirm
elig
requir
particip
screen
educ
process
requir
prior
enrol
ensur
subject
comprehend
purpos
detail
studi
phase
studi
establish
safeti
primeboost
vaccin
schedul
healthi
individu
limit
adult
year
old
time
enrol
prior
sign
vrc
inform
consent
elig
volunt
take
short
assess
understand
quiz
test
understand
vaccin
studi
incorrect
answer
explain
volunt
sign
inform
consent
document
studi
coordin
satisfi
understand
studi
particip
must
meet
follow
criteria
year
old
week
studi
abl
provid
proof
ident
satisfact
studi
clinician
complet
enrol
process
complet
assess
understand
prior
enrol
verbal
understand
question
answer
incorrectli
abl
will
complet
inform
consent
process
will
receiv
hiv
test
result
will
abid
nih
guidelin
partner
notif
posit
hiv
result
will
donat
blood
sampl
storag
use
futur
research
will
discuss
hiv
infect
risk
amen
risk
reduct
counsel
good
gener
health
without
clinic
signific
medic
histori
physic
examin
laboratori
result
without
clinic
signific
find
bodi
mass
index
bmi
less
within
day
prior
enrol
hemoglobin
gdl
women
gdl
men
white
blood
cell
wbc
cellsmm
woman
breastfeed
plan
becom
pregnant
week
studi
particip
hiv
vaccin
prior
clinic
trial
immunosuppress
medic
cytotox
medic
inhal
corticosteroid
within
past
six
month
except
corticosteroid
nasal
spray
allerg
rhiniti
topic
corticosteroid
acut
uncompl
dermat
blood
product
within
day
prior
hiv
screen
immunoglobulin
within
day
prior
hiv
screen
investig
research
agent
within
day
prior
initi
studi
vaccin
administr
live
attenu
vaccin
within
day
prior
initi
studi
vaccin
administr
medic
indic
subunit
kill
vaccin
eg
influenza
pneumococc
allergi
treatment
antigen
inject
within
day
studi
vaccin
administr
current
antituberculosi
prophylaxi
therapi
seriou
advers
reaction
vaccin
anaphylaxi
hive
respiratori
difficulti
angioedema
abdomin
pain
autoimmun
diseas
immunodefici
asthma
unstabl
requir
emerg
care
urgent
care
hospit
intub
past
two
year
requir
use
oral
intraven
corticosteroid
diabet
mellitu
type
ii
except
gestat
diabet
histori
thyroidectomi
thyroid
diseas
requir
medic
within
past
month
seriou
angioedema
episod
within
previou
year
requir
medic
previou
two
year
hypertens
well
control
medic
enrol
bleed
disord
diagnos
doctor
eg
factor
defici
coagulopathi
platelet
disord
requir
special
precaut
signific
bruis
bleed
difficulti
im
inject
blood
draw
syphili
infect
activ
posit
serolog
due
syphili
infect
treat
less
six
month
ago
malign
activ
treat
malign
reason
assur
sustain
cure
malign
like
recur
period
studi
seizur
disord
febril
seizur
age
two
seizur
secondari
alcohol
withdraw
year
ago
singular
seizur
requir
treatment
within
last
year
asplenia
function
asplenia
condit
result
absenc
remov
spleen
psychiatr
condit
preclud
complianc
protocol
past
present
psychos
past
present
bipolar
disord
disord
requir
lithium
within
five
year
prior
enrol
histori
suicid
plan
attempt
medic
psychiatr
social
condit
occup
reason
respons
judgment
investig
contraind
protocol
particip
impair
volunt
abil
give
inform
consent
subject
health
risk
factor
note
exclud
current
smoker
quit
smoke
less
day
prior
enrol
bmi
fast
low
densiti
lipoprotein
ldl
mgdl
fast
cholesterol
mgdl
systol
blood
pressur
mm
hg
diastol
blood
pressur
mm
hg
fast
blood
glucos
mgdl
note
fast
blood
test
requir
hour
fast
prior
blood
draw
result
use
elig
screen
must
test
complet
week
day
prior
day
enrol
individu
criteria
bmi
inclus
item
blood
pressur
exclus
item
must
also
met
evalu
safeti
vaccin
includ
laboratori
studi
medic
histori
physic
assess
clinician
subject
selfassess
record
diari
card
potenti
advers
reaction
evalu
prior
continu
immun
schedul
blood
test
immun
respons
perform
vaccin
research
center
studi
schedul
describ
section
present
form
product
protocol
date
novemb
protocol
vrc
version
differenti
prothrombin
time
pt
partial
thromboplastin
time
ptt
chemistri
panel
includ
fast
glucos
cholesterol
ldl
quantit
immunoglobulin
rapid
plasma
reagin
rpr
hepat
b
surfac
antigen
antihepat
c
antibodi
hcv
pcr
antidsdna
hiv
elisawestern
blot
hiv
pcr
tcell
subset
adenoviru
serolog
urinalysi
pregnanc
test
femal
reproduct
potenti
question
regard
sexual
behavior
practic
adenoviru
serolog
use
random
well
fast
glucos
cholesterol
ldl
use
elig
screen
must
within
week
day
prior
enrol
test
specif
elig
requir
must
done
within
window
need
meet
studi
elig
risk
statu
hiv
infect
determin
seri
question
design
identifi
risk
factor
storag
sampl
peripher
blood
mononuclear
cell
pbmc
serum
also
collect
gener
elig
clinic
trial
depend
result
laboratori
test
answer
interview
question
inform
consent
document
vaccin
trial
review
counsel
relat
potenti
risk
becom
pregnant
trial
avoid
hiv
infect
provid
assess
understand
vrc
complet
day
subject
schedul
enrol
vrc
day
defin
day
vrc
enrol
first
inject
vrc
elig
review
day
part
enrol
process
subject
begin
primeboost
schedul
day
enrol
first
dna
vaccin
pregnanc
test
result
women
reproduct
potenti
must
neg
obtain
inject
day
prior
studi
inject
day
evalu
prior
first
inject
baselin
subsequ
safeti
assess
refer
item
list
section
tabl
appendix
iii
detail
type
evalu
must
complet
schedul
dna
vaccin
day
day
day
least
day
inject
day
rad
booster
vaccin
schedul
close
day
possibl
day
day
window
permit
schedul
vaccin
administ
deltoid
muscl
mg
dose
use
either
needl
syring
biojector
needlefre
inject
system
accord
random
assign
neither
clinic
staff
subject
know
advanc
devic
random
assign
sequenti
enrolle
studi
inject
devic
use
known
clinic
staff
subject
complet
subject
enrol
studi
vaccin
administ
deltoid
muscl
use
needl
syring
subject
randomli
assign
either
pu
pu
rad
boost
dose
dose
assign
blind
clinic
staff
subject
subject
complet
safeti
immunogen
evalu
week
booster
inject
protocol
statistician
prepar
random
plan
dna
vaccin
inject
devic
rad
vaccin
booster
dose
provid
site
pharmaci
inject
prepar
prior
dna
vaccin
photo
deltoid
area
inject
taken
follow
studi
inject
dna
vaccin
rad
vaccin
subject
observ
minimum
minut
vital
sign
temperatur
blood
pressur
puls
respiratori
rate
complet
minut
postimmun
inject
site
inspect
evid
local
reaction
subject
given
diari
card
record
temperatur
symptom
daili
day
followup
dna
vaccin
subject
clinic
visit
day
follow
dna
inject
visit
includ
interim
histori
vital
sign
lymph
node
exam
examin
vaccin
site
erythema
indur
skin
lesion
document
measur
perpendicular
diamet
photograph
vaccin
site
taken
whether
find
evid
skin
lesion
visit
day
vaccin
also
clinic
visit
otherwis
followup
first
telephon
clinic
visit
schedul
subject
report
chang
suggest
skin
lesion
may
form
attempt
made
photograph
vaccin
site
distanc
time
similar
light
condit
tag
metric
ruler
subject
number
date
visit
identifi
place
vaccin
site
prior
photograph
diari
card
collect
first
clinic
visit
dna
vaccin
complet
day
dna
inject
studi
subject
evalu
clinic
visit
includ
interim
histori
vital
sign
lymph
node
exam
examin
vaccin
site
collect
urin
blood
sampl
photograph
taken
skin
lesion
need
document
resolut
find
present
prior
visit
follow
dna
vaccin
inject
skin
biopsi
option
assess
skin
lesion
appear
form
skin
biopsi
includ
studi
research
purpos
better
understand
etiolog
ie
distinguish
immun
allerg
infecti
foreign
bodi
reaction
skin
lesion
sometim
associ
dna
vaccin
subject
may
refus
skin
biopsi
prefer
timepoint
obtain
skin
biopsi
earliest
visit
vaccin
evid
skin
lesion
expect
day
postvaccin
case
may
earlier
later
depend
upon
individu
circumst
subject
ask
two
skin
biopsi
dna
vaccin
site
skin
lesion
howev
skin
biopsi
recommend
clinic
care
purpos
addit
skin
biopsi
may
done
subject
consent
followup
visit
week
day
includ
interim
histori
vital
sign
lymph
node
exam
collect
blood
sampl
first
followup
perform
telephon
first
second
day
follow
rad
inject
clinic
visit
occur
indic
telephon
interview
event
report
telephon
interview
requir
clinic
visit
includ
rash
urticaria
hive
fever
grade
higher
signific
impair
activ
daili
live
adl
day
rad
inject
studi
subject
evalu
clinic
visit
visit
includ
interim
histori
vital
sign
lymph
node
exam
examin
vaccin
site
diari
card
collect
interv
throughout
studi
subject
blood
drawn
immunolog
assay
cell
serum
plasma
use
store
futur
virolog
immunolog
assay
subject
also
interview
final
clinic
visit
regard
social
harm
includ
problem
employ
travel
immigr
access
insur
medic
dental
care
neg
reaction
famili
friend
cowork
studi
visit
procedur
test
last
clinic
visit
follow
vrc
assess
understand
quiz
day
signatur
studi
particip
inform
consent
form
vrc
day
clinic
evalu
vital
sign
weight
everi
visit
day
axillari
lymph
node
exam
vaccin
visit
followup
visit
week
vaccin
target
physic
exam
visit
indic
interim
complaint
laboratori
find
interim
medic
histori
everi
visit
counsel
hiv
avoid
pregnanc
day
offer
everi
subsequ
visit
studi
inject
refer
studi
schema
postinject
vital
sign
assess
inject
site
minut
studi
inject
diari
card
baselin
day
inject
diari
card
selfassess
subject
follow
inject
diari
card
includ
paramet
unusu
tiredfeel
unwel
muscl
ach
inject
site
headach
chill
nausea
paintend
inject
site
subject
also
record
highest
measur
temperatur
measur
perpendicular
diamet
red
swell
inject
site
note
evid
skin
lesion
vaccin
site
diari
card
collect
earliest
clinic
visit
inject
card
complet
note
assay
perform
immedi
rather
complet
use
frozen
sampl
later
date
intracellular
cytokin
stain
ic
elispot
assay
day
week
note
assay
perform
immedi
rather
complet
use
frozen
sampl
later
date
pbmc
plasma
storag
save
blood
collect
assay
social
impact
questionnair
week
social
impact
questionnair
includ
paramet
person
relationship
travel
immigr
employ
educ
medic
dental
health
insur
life
insur
hous
militaryoth
govern
agenc
week
longterm
followup
week
clinic
visit
subject
contact
one
year
later
subject
encourag
return
clinic
visit
week
day
interview
interv
lifethreaten
advers
event
persist
signific
disabilityincapac
nonelect
hospit
new
chronic
diseas
requir
ongo
medic
manag
medic
outcom
pregnanc
includ
congenit
anomaliesbirth
defect
well
hiv
test
elisa
western
blot
posit
hiv
pcr
research
immunolog
blood
draw
pbmc
plasma
serum
subject
may
opt
contact
telephon
mail
email
allow
collect
interview
inform
specifi
without
followup
blood
draw
subject
death
interv
week
week
attempt
made
obtain
inform
caus
death
followup
test
vaccineinduc
hiv
antibodi
permit
year
week
visit
see
section
subject
may
also
contact
time
confirm
contact
inform
provid
notif
releas
studi
result
inform
rad
vaccin
dose
assign
readi
made
known
subject
possibl
vaccin
regimen
induc
immunolog
respons
detect
standard
hiv
screen
techniqu
even
though
vaccin
caus
hiv
infect
follow
step
taken
ensur
detect
hiv
infect
protect
particip
advers
consequ
associ
hiv
antibodi
test
indic
antibodi
respons
vaccin
studi
particip
receiv
regularli
schedul
counsel
regard
avoid
hiv
infect
accord
recent
cdc
hiv
counsel
guidelin
studi
particip
screen
hiv
infect
period
particip
studi
see
appendix
iii
schedul
test
clinic
laboratori
indic
hiv
infect
test
requir
make
definit
diagnosi
includ
western
blot
analysi
viral
load
measur
pcr
test
perform
confirm
test
perform
soon
possibl
posit
antibodi
respons
identifi
particip
promptli
inform
hivinfect
particip
found
vaccineinduc
antibodi
respons
evid
hiv
infect
inform
hivinfect
written
document
describ
vaccineinduc
antibodi
respons
confirm
data
provid
studi
complet
suffici
evid
antibodi
respons
date
test
result
vaccin
natur
occur
infect
particip
vaccineinduc
antibodi
provid
opportun
hiv
antibodi
test
annual
five
year
monitor
serolog
statu
particip
counsel
regard
potenti
antibodi
respons
implic
respons
prior
particip
studi
vaccin
caus
hiv
infect
subject
becom
hiv
infect
due
caus
particip
studi
refer
medic
care
treatment
manag
diseas
may
given
opportun
enrol
appropri
studi
acut
hiv
infect
longterm
followup
studi
one
avail
nih
investig
respons
provid
ongo
medic
care
antiretrovir
medic
event
infect
concomit
medic
record
screen
everi
studi
visit
concomit
medic
elig
criteria
enrol
continu
appli
subject
remain
elig
studi
inject
enrol
subject
develop
need
medic
prohibit
elig
criteria
studi
inject
discontinu
fdaapprov
live
attenu
vaccin
requir
immedi
medic
need
studi
inject
must
discontinu
fdaapprov
subunit
kill
vaccin
requir
immedi
medic
need
must
given
least
day
day
studi
inject
subject
remain
elig
addit
studi
inject
imperil
subject
health
fdaapprov
vaccin
defer
least
day
final
studi
inject
subject
receiv
least
one
studi
inject
continu
clinic
laboratori
evalu
specifi
studi
month
followup
certain
circumst
subject
termin
particip
inject
particip
discontinu
addit
studi
vaccin
continu
follow
accord
schedul
safeti
immunogen
evalu
except
followup
evalu
specif
safeti
followup
vaccin
need
complet
vaccin
given
refer
appendix
iii
b
c
visit
follow
dna
vaccin
b
visit
follow
rad
vaccin
specif
event
requir
withdraw
subject
vaccin
grade
advers
event
classifi
possibl
associ
immun
resolv
baselin
time
next
schedul
immun
grade
advers
event
classifi
probabl
definit
associ
immun
except
grade
paintend
fatiguemalais
nausea
headach
chill
myalgia
grade
system
inject
site
advers
event
classifi
possibl
probabl
definit
associ
immun
type
hypersensit
associ
immun
seriou
intercurr
ill
expect
resolv
prior
next
schedul
immun
treatment
system
glucocorticoid
eg
prednison
glucocorticoid
immunomodul
nsaid
reason
medic
need
concomit
vaccin
period
studi
vaccin
requir
discontinu
studi
vaccin
schedul
see
section
repeat
failur
compli
protocol
requir
ind
sponsor
studi
sponsor
princip
investig
decid
stop
cancel
studi
irb
fda
request
studi
stop
princip
investig
close
monitor
analyz
studi
data
becom
avail
make
determin
regard
presenc
sever
advers
event
daid
medic
offic
provid
independ
review
advers
event
bear
studi
stop
follow
review
fda
novemb
halt
rad
booster
vaccin
grade
fever
agre
protocol
need
halt
sign
symptom
consist
selflimit
fever
flulik
syndrom
may
occur
rad
postvaccin
period
therefor
protocol
section
amend
grade
grade
postvaccin
reactogen
advers
event
paintend
fever
malais
fatigu
headach
chill
nausea
myalgia
arthralgia
review
ind
sponsor
medic
offic
princip
investig
weekli
safeti
monitor
review
see
section
vaccin
ongo
quarterli
safeti
monitor
report
submit
ind
subject
complet
least
week
followup
rad
booster
vaccin
administr
studi
inject
new
enrol
halt
ind
sponsor
promptli
notifi
accord
criteria
follow
count
event
type
list
done
investig
vaccin
separ
one
subject
experi
grade
advers
event
assess
possibl
probabl
definit
relat
studi
vaccin
one
subject
experi
grade
advers
event
assess
possibl
probabl
definit
relat
studi
vaccin
criterion
appli
erythema
indur
vomit
laboratori
abnorm
clinic
advers
experi
appli
local
system
postvaccin
advers
event
paintend
fever
malais
fatigu
headach
chill
nausea
myalgia
arthralgia
one
subject
experi
grade
erythema
indur
inject
site
two
subject
experi
grade
higher
advers
event
assess
possibl
probabl
definit
relat
vaccin
criterion
appli
vomit
laboratori
abnorm
clinic
advers
experi
appli
local
system
postvaccin
advers
event
paintend
fever
malais
fatigu
headach
chill
nausea
myalgia
arthralgia
studi
inject
enrol
would
resum
review
advers
event
caus
halt
result
recommend
permit
studi
inject
studi
enrol
review
make
decis
occur
follow
grade
event
meet
stop
criteria
ind
sponsor
consult
princip
investig
conduct
review
make
decis
resum
close
studi
grade
event
lead
halt
grade
grade
event
meet
stop
criteria
ind
sponsor
particip
princip
investig
consult
fda
conduct
review
make
decis
resum
close
studi
grade
grade
advers
event
meet
criteria
halt
studi
safeti
data
report
chang
studi
statu
submit
irb
promptli
accord
section
institut
polici
advers
event
unfavor
unintend
chang
bodi
structur
bodi
function
laboratori
result
associ
tempor
use
studi
treatment
whether
consid
relat
studi
treatment
advers
event
grade
accord
term
seriou
advers
drug
experi
defin
cfr
follow
advers
drug
experi
occur
dose
result
follow
outcom
death
lifethreaten
advers
drug
experi
inpati
hospit
prolong
exist
hospit
persist
signific
disabilityincapac
congenit
anomalybirth
defect
import
medic
event
may
result
death
lifethreaten
requir
hospit
may
consid
seriou
advers
drug
experi
base
upon
appropri
medic
judgment
may
jeopard
subject
requir
medic
surgic
intervent
prevent
one
outcom
list
definit
exampl
medic
event
includ
allerg
bronchospasm
requir
intens
treatment
emerg
room
home
blood
dyscrasia
convuls
result
inpati
hospit
develop
drug
depend
drug
abus
section
term
expedit
advers
event
eae
encompass
event
would
consid
sae
cfr
definit
inform
advers
event
ae
collect
studi
nurs
clinic
staff
enter
comput
databas
princip
investig
studi
coordin
review
data
ongo
basi
ae
report
expedit
basi
must
document
daid
expedit
advers
event
report
form
eae
report
form
avail
rcc
websit
http
rcctechresintlcom
rcc
contact
inform
provid
appendix
ii
studi
use
standard
level
expedit
ae
report
defin
daid
eae
manual
briefli
summar
standard
level
report
requir
complet
eae
report
form
follow
type
ae
occur
exposur
studi
agent
result
death
regardless
relationship
studi
agent
congenit
anomali
birth
defect
fetal
loss
regardless
relationship
studi
agent
result
persist
signific
disabl
incapac
regardless
relationship
studi
agent
suspect
advers
drug
reaction
ie
definit
probabl
possibl
probabl
relat
studi
agent
requir
hospit
prolong
exist
hospit
requir
intervent
prevent
significantperman
disabl
death
addit
event
regardless
grade
judgment
site
investig
repres
seriou
advers
event
may
report
ind
sponsor
eae
ae
must
report
expedit
basi
standard
level
protocoldefin
eae
report
period
studi
studi
enrol
last
requir
clinic
visit
week
discontinu
subject
studi
particip
reason
end
protocoldefin
eae
report
period
state
site
must
report
seriou
unexpect
clinic
suspect
advers
vaccin
reaction
studi
site
staff
becom
awar
event
passiv
basi
ie
publicli
avail
inform
studi
agent
must
consid
determin
relationship
ae
requir
expedit
report
daid
grade
sever
event
tabl
grade
sever
adult
advers
event
divis
aid
tabl
grade
sever
adult
pediatr
advers
event
version
dec
see
appendix
iv
eae
report
must
report
eae
form
submit
clinic
site
ind
sponsor
daid
regulatori
complianc
center
rcc
safeti
offic
rccsafetyoffic
techrescom
soon
possibl
later
work
day
clinic
site
becom
awar
event
meet
criteria
ind
sponsor
respons
submit
ind
safeti
report
fda
necessari
per
cfr
daid
submit
ind
safeti
report
soon
possibl
later
day
initi
receipt
inform
advers
event
report
requir
niaid
institut
review
board
irb
protocol
follow
investig
submit
complet
seriou
advers
event
report
niaid
irb
within
day
becom
awar
subject
death
potenti
lifethreaten
grade
seriou
advers
event
possibl
probabl
definit
relat
investig
agent
inpati
hospit
elect
persist
signific
disabilityincapac
congenit
anomalybirth
defect
investig
submit
complet
seriou
advers
event
report
niaid
irb
within
day
becom
awar
grade
sever
advers
event
possibl
probabl
definit
relat
investig
agent
investig
report
within
day
event
condit
regardless
grade
judgment
repres
event
report
irb
investig
forward
ind
safeti
report
relat
fda
commun
irb
within
day
receipt
summari
advers
event
report
niaid
irb
submiss
request
continu
review
institut
biosafeti
committe
ibc
respons
review
research
use
recombin
dna
complianc
nih
guidelin
keep
ibc
requir
sae
report
sent
irb
provid
ibc
time
studi
singlecent
random
trial
assess
safeti
toler
schedul
hiv
dna
plasmid
vaccin
follow
one
either
pu
pu
hiv
adenovir
vector
rad
booster
vaccin
either
needl
syring
ns
biojector
hivuninfect
adult
preliminari
assess
immunogen
also
perform
primari
object
evalu
safeti
toler
human
primeboost
vaccin
regimen
secondari
object
includ
evalu
immunogen
vaccin
regimen
develop
adenoviru
serotyp
neutral
antibodi
social
impact
particip
vaccin
trial
studi
provid
preliminari
inform
whether
devic
use
dna
vaccin
result
similar
safeti
immunogen
whether
preenrol
adenoviru
serotyp
antibodi
titer
affect
safeti
immun
respons
rad
booster
vaccin
assess
product
safeti
includ
clinic
observ
monitor
hematolog
chemic
paramet
safeti
close
monitor
inject
evalu
week
follow
adenovir
vector
booster
vaccin
see
section
appendix
iii
detail
specifi
time
point
follow
paramet
assess
local
reactogen
sign
symptom
princip
immunogen
endpoint
cellular
immun
respons
measur
week
baselin
week
third
dna
vaccin
week
ad
vaccin
booster
consist
cell
respons
measur
intracellular
cytokin
stain
ic
elispot
assay
cell
assay
studi
timepoint
well
humor
immun
respons
measur
hivspecif
antibodi
assay
complet
exploratori
evalu
social
impact
variabl
measur
questionnair
last
clinic
visit
includ
neg
experi
problem
particip
experienc
due
hisher
particip
studi
follow
social
impact
follow
cours
studi
person
relationship
travel
immigr
employ
educ
medic
dental
care
health
insur
life
insur
hous
militaryoth
govern
agenc
impact
identifi
particip
recruit
target
healthi
hivuninfect
adult
particip
age
year
old
studi
plan
subject
receiv
three
inject
mg
investig
vaccin
one
two
method
either
needl
syring
biojector
needleless
inject
system
follow
booster
vaccin
week
requir
clinic
followup
studi
week
sampl
size
subject
safeti
data
primeboost
regimen
evalu
use
factori
design
follow
sampl
size
appli
biojector
dna
vaccin
prime
n
needl
syring
dna
vaccin
prime
pu
rad
booster
vaccin
pu
rad
booster
vaccin
random
sequenc
obtain
computergener
random
number
provid
studi
pharmacist
statistician
studi
number
use
random
subject
low
titer
studi
number
use
random
subject
high
titer
within
stratum
studi
number
randomli
assign
combin
dna
inject
devic
rad
dose
subject
receiv
subject
high
low
titer
enrol
simultan
pharmacist
statistician
respons
maintain
secur
treatment
assign
maintain
blind
discuss
treatment
assign
vrc
clinician
pharmaci
staff
prohibit
assign
permit
known
decreas
potenti
particip
dropout
period
random
initi
vaccin
random
occur
day
studi
consent
sign
elig
confirm
studi
number
assign
complet
elig
checklist
electron
studi
databas
next
sequenti
number
studi
number
sequenc
subject
titer
categori
assign
biojector
needlesyring
dna
vaccin
becom
known
subject
protocol
staff
shortli
studi
enrol
devic
use
dna
vaccin
evid
rad
boost
dosag
blind
week
safeti
immunogen
evalu
rad
boost
complet
subject
receiv
rad
boost
point
assess
vaccin
acut
reactogen
short
term
advers
event
complet
knowledg
rad
dosag
influenc
reactogen
assess
goal
safeti
evalu
studi
identifi
safeti
concern
associ
inject
sampl
size
calcul
safeti
express
term
abil
detect
seriou
advers
experi
abil
studi
identifi
seriou
advers
experi
best
express
maximum
true
rate
event
would
unlik
observ
minimum
true
rate
event
would
like
observ
specif
chanc
observ
least
seriou
advers
experi
volunt
true
rate
event
least
chanc
would
observ
least
seriou
advers
experi
true
rate
less
probabl
observ
seriou
advers
experi
among
sampl
size
present
tabl
rang
possibl
true
event
rate
calcul
provid
complet
pictur
sensit
studi
design
identifi
potenti
safeti
problem
vaccin
primari
goal
trial
regard
immunogen
outcom
preliminari
estim
respons
rate
definit
respons
base
compar
percent
respond
cell
stimul
background
level
specif
person
time
point
statist
test
use
determin
percent
respond
cell
significantli
higher
background
consid
respons
time
point
falseposit
rate
built
statist
criteria
method
valid
hivposit
hivneg
sampl
tabl
applic
immunogen
respons
rate
give
exact
confid
interv
possibl
number
respons
volunt
exampl
observ
respons
among
vaccine
exact
binomi
confid
interv
true
rate
rang
also
interest
estim
immunolog
respons
among
vaccine
receiv
two
method
inject
well
among
receiv
dosag
rad
vaccin
among
two
strata
defin
titer
respons
rate
group
base
particip
studi
power
detect
differ
group
would
unlik
declar
statist
signific
unless
true
differ
extrem
tabl
give
power
detect
differ
variou
proport
two
group
size
least
power
detect
differ
would
need
expect
differ
approxim
two
group
sinc
enrol
concurr
receiv
first
studi
vaccin
particip
receiv
least
one
vaccin
therefor
provid
safeti
data
statist
analys
perform
use
sa
splu
statist
softwar
formal
multipl
comparison
adjust
employ
safeti
endpoint
secondari
endpoint
impact
variabl
primari
secondari
object
analys
baselin
characterist
includ
demograph
laboratori
measur
summar
use
descript
statist
number
percentag
particip
experienc
type
reactogen
sign
symptom
tabul
sever
given
sign
symptom
particip
reactogen
count
maximum
sever
assess
advers
experi
ae
code
meddra
prefer
term
number
percentag
particip
experienc
specif
advers
event
tabul
sever
relationship
treatment
calcul
tabl
particip
advers
experi
count
maximum
sever
strongest
record
causal
relationship
treatment
advers
experi
follow
vaccin
needl
syring
summar
separ
ae
follow
vaccin
biojector
advers
experi
occur
booster
vaccin
week
booster
vaccin
summar
separ
complet
list
advers
experi
particip
provid
detail
includ
sever
relationship
treatment
type
onset
durat
outcom
boxplot
local
laboratori
valu
gener
baselin
valu
valu
measur
cours
studi
boxplot
show
quartil
median
quartil
outlier
valu
outsid
boxplot
also
plot
appropri
horizont
line
repres
boundari
abnorm
valu
plot
statist
analysi
immunogen
employ
intenttotreat
principl
ie
data
enrol
particip
use
except
exclud
data
hivinfect
particip
post
infect
hiv
posit
statu
infect
particip
unknown
time
first
sampl
immunogen
assess
drawn
data
particip
exclud
analysi
assay
data
qualit
ie
posit
neg
analys
perform
tabul
frequenc
posit
respons
assay
time
point
assess
perform
binomi
respons
rate
present
correspond
exact
confid
interv
estim
respons
rate
strata
inject
method
ad
boost
summar
conting
tabl
compar
use
fisher
exact
test
miss
respons
assum
miss
random
ie
condit
observ
data
missing
independ
unobserv
respons
respons
also
given
immunolog
assay
underli
continu
counttyp
readout
often
dichotom
respondernonrespond
categori
assay
graphic
tabular
summari
underli
distribut
made
summari
may
perform
transform
data
eg
log
transform
better
satisfi
assumpt
symmetri
homoscedast
social
impact
tabul
type
event
impact
qualiti
life
number
percentag
particip
experienc
type
social
impact
also
tabul
impact
qualiti
life
calcul
multipl
event
type
particip
count
maximum
impact
postvaccin
visit
addit
list
gener
particip
experienc
major
disturb
qualiti
life
due
studi
particip
list
includ
social
impact
experienc
particip
descript
impact
impact
qualiti
life
whether
resolut
interim
analys
immunogen
perform
ic
assay
includ
week
complet
prime
vaccin
complet
particip
week
complet
booster
vaccin
complet
particip
purpos
report
provid
basic
immunogen
data
inform
make
futur
clinic
trial
developmentrel
decis
time
manner
devic
use
dna
vaccin
blind
protocol
plan
state
dose
rad
use
subject
unblind
complet
six
week
followup
rad
vaccin
result
interim
immunogen
analysi
way
influenc
conduct
vrc
trial
term
earli
termin
complet
later
safeti
immunogen
endpoint
assess
vaccin
ship
studi
pharmacist
dri
ice
store
c
use
vial
vaccin
remov
freezer
allow
equilibr
room
temperatur
prior
inject
one
ml
inject
mgml
prepar
administ
mg
dose
vial
may
store
durat
studi
exceed
year
vial
refrozen
thaw
test
stabil
accord
ich
guidelin
similar
plasmid
shown
stabl
minimum
month
store
hour
store
room
temperatur
vial
intend
singl
use
singl
use
vial
sent
unblind
nih
clinic
center
pharmaci
vial
label
note
storag
temperatur
c
c
product
may
store
freezer
temperatur
low
howev
deviat
storag
temperatur
c
occur
site
pharmacist
must
report
storag
temperatur
deviat
promptli
ind
sponsor
product
ship
dri
ice
product
temperatur
maintain
prior
ship
vial
seal
mylar
bag
prevent
co
inactiv
adenovir
vector
product
product
vial
kept
dri
ice
without
protect
product
receiv
clinic
site
remov
promptli
dri
ice
packag
mylar
bag
store
note
investig
vaccin
vial
provid
two
differ
concentr
x
puml
x
puml
vaccin
vial
contain
mlvial
vial
may
store
durat
studi
exceed
two
year
lot
releas
form
note
number
particl
unit
pu
final
product
clinic
protocol
specifi
dose
particl
unit
pu
particl
unit
number
viral
particl
activ
found
product
determin
spectrophotometri
particl
unit
rather
plaqu
form
unit
pfu
fluoresc
form
unit
ffu
use
determin
dose
potenti
toxic
host
immun
respons
viral
particl
regardless
abil
infect
target
cell
also
accur
measur
either
pfu
ffu
highli
depend
methodolog
thu
variabl
furthermor
fda
recombin
dna
advisori
committe
recommend
use
pu
studi
inject
administ
deltoid
muscl
studi
inject
must
administ
within
hour
remov
vaccin
vial
freezer
biojector
needlefre
inject
manag
system
use
direct
compani
neither
materi
inject
deltoid
inject
site
skin
prepar
requir
deviat
standard
procedur
inject
site
disinfect
area
allow
dri
complet
skin
around
inject
site
held
firmli
syring
place
inject
site
angl
actuat
press
materi
releas
muscl
continu
hold
firmli
second
inject
site
cover
steril
cover
pressur
appli
finger
minut
biojector
util
steril
singleus
syring
variabl
dose
ml
medic
administr
studi
agent
deliv
pressur
compress
co
ga
cartridg
store
insid
biojector
biojector
actuat
depress
co
releas
caus
plunger
push
studi
agent
steril
syring
skin
underli
tissu
studi
agent
expel
microorific
high
veloc
fraction
second
pierc
skin
co
come
contact
inject
syring
design
prevent
back
splatter
contamin
devic
tissu
subject
test
biojector
administr
vaccin
demonstr
effect
immun
respons
although
use
associ
selflimit
pain
red
swell
inject
site
method
administr
well
toler
offer
advantag
elimin
needl
stick
accid
clinic
system
fda
clearanc
deliv
intramuscular
inject
vaccin
individu
syring
prepar
pharmaci
label
subject
identifi
transport
clinic
clinician
administ
inject
select
needl
length
inch
depend
subject
arm
size
order
ensur
intramuscular
inject
use
needl
syring
dispos
medic
wast
sharp
contain
sharp
contain
dispos
medic
patholog
wast
mpw
contain
inciner
accord
subject
studi
agent
assign
ml
volum
withdrawn
appropri
vial
type
administr
plan
inject
administr
use
standard
intramuscular
inject
techniqu
follow
administ
one
ml
inject
x
puml
prepar
pu
dose
administ
one
ml
inject
x
puml
prepar
individu
syring
prepar
pharmaci
label
subject
identifi
transport
clinic
clinician
administ
inject
select
needl
length
inch
depend
subject
arm
size
order
ensur
intramuscular
inject
vial
individu
label
name
materi
dose
ph
volum
lot
number
concentr
storag
instruct
investig
use
statement
caution
new
drug
limit
feder
law
investig
use
manufactur
inform
necessari
addit
lot
vaccin
produc
subject
random
receiv
rad
vaccin
pu
pu
subject
clinic
staff
princip
investig
blind
treatment
alloc
safeti
immunogen
evalu
week
rad
inject
complet
pharmacist
primari
respons
drug
dispens
keep
random
code
provid
protocol
statistician
studi
pharmacist
respons
prepar
syring
vaccin
dose
indic
subject
random
assign
label
subject
identif
pharmacist
individu
respons
clinic
followup
conduct
studi
rad
dosag
blind
subject
complet
six
week
followup
blind
rad
dosag
broken
earli
opinion
princip
investig
immedi
unblind
subject
dosag
assign
necessit
acut
safeti
concern
know
dosag
receiv
would
chang
type
medic
care
need
best
treat
subject
health
problem
pi
would
request
pharmaci
provid
rad
dosag
inform
pi
would
promptli
notifi
daid
medic
offic
protocol
statistician
irb
subject
dosag
assign
unblind
earlier
specifi
protocol
studi
pharmacist
respons
maintain
accur
record
code
inventori
account
record
vaccin
suppli
studi
electron
document
well
paper
copi
use
empti
vial
unus
portion
vial
discard
biohazard
contain
bag
inciner
autoclav
unopen
vial
remain
end
studi
return
product
facil
discard
discret
sponsor
accord
polici
appli
investig
agent
partial
use
vial
administ
subject
use
vitro
experiment
studi
dispos
accord
institut
pharmaci
polici
studi
inform
consent
provid
appendix
describ
investig
product
use
aspect
involv
protocol
particip
subject
particip
studi
investig
respons
obtain
written
inform
consent
subject
adequ
explan
aim
method
anticip
benefit
potenti
hazard
studi
protocolspecif
procedur
studi
medic
administ
acquisit
inform
consent
document
subject
medic
record
requir
cfr
inform
consent
form
sign
person
date
subject
person
conduct
inform
consent
discuss
origin
sign
inform
consent
form
retain
medic
chart
copi
provid
subject
risk
note
dna
vaccin
base
risk
inject
risk
vaccin
gener
interim
result
previou
phase
studi
vaccin
well
investig
dna
vaccin
potenti
side
effect
result
intramuscular
inject
includ
sting
arm
discomfort
red
skin
vaccin
inject
site
subject
may
exhibit
gener
sign
symptom
associ
administr
vaccin
inject
includ
fever
chill
rash
ach
pain
nausea
headach
dizzi
fatigu
side
effect
monitor
gener
short
term
requir
treatment
studi
subject
may
self
administ
medic
acetaminophen
nonsteroid
antiinflammatori
drug
nsaid
antihistamin
requir
glucocorticoid
use
studi
subject
medic
requir
studi
subject
receiv
immun
continu
monitor
followup
visit
potenti
risk
dna
vaccin
includ
muscl
damag
antibodi
dna
insert
vaccin
dna
genom
dna
potenti
cancer
risk
insert
vaccin
dna
bacteria
viru
although
risk
possibl
observ
date
laboratori
anim
human
test
dna
plasmid
vaccin
extens
human
experi
multiclad
dna
vaccin
studi
studi
vrc
subject
enrol
receiv
vaccin
receiv
placebo
random
studi
unblind
septemb
placebo
vaccin
recipi
note
occasion
asymptomat
selflimit
chang
glucos
bilirubin
liver
enzym
urin
protein
vaccin
group
three
report
advers
event
possibl
relat
vaccin
grade
asymptomat
neutropenia
seen
test
result
day
vaccin
mg
group
normal
repeat
test
day
later
grade
urticaria
onset
day
vaccin
mg
group
grade
maculopapular
rash
onset
day
vaccin
urticaria
includ
concomit
bladder
infect
yeast
infect
multipl
antibiot
rash
result
discontinu
vaccin
schedul
inject
clinic
consist
either
drug
erupt
viral
exanthem
inform
consent
protocol
use
similar
dna
vaccin
note
potenti
risk
neutropenia
rash
hive
extramur
random
blind
studi
vaccin
ongo
multiclad
dna
vaccin
use
studi
administ
subject
openlabel
studi
vrc
subject
report
fever
follow
vaccin
reactogen
none
mild
except
two
subject
report
moder
inject
site
pain
one
subject
report
moder
nausea
malais
one
grade
advers
event
chronic
urticaria
possibl
relat
vaccin
requir
expedit
report
ind
sponsor
date
two
moder
grade
advers
event
possibl
attribut
vaccin
intermitt
dizzi
day
durat
begin
day
second
vaccin
one
subject
subject
receiv
third
vaccin
without
recurr
symptom
asymptomat
hypoglycemia
anoth
subject
first
note
followup
visit
day
third
vaccin
four
inject
associ
mild
skin
lesion
cm
diamet
vaccin
site
small
scab
form
within
week
immun
came
day
skin
heal
without
treatment
within
week
one
skin
biopsi
obtain
day
post
vaccin
show
subcutan
dermal
perivascular
lymphocyt
inflamm
rare
eosinophil
rare
giant
cell
note
infiltr
compos
entir
posit
cell
includ
process
appear
primarili
subcutan
inflammatori
respons
vaccin
cutan
manifest
seriou
advers
event
date
limit
human
experi
adenovir
vector
vaccin
previous
administ
nih
clinic
center
first
phase
studi
human
first
extramur
studi
use
vaccin
open
novemb
pu
dose
none
subject
first
phase
studi
fever
reactogen
mild
none
next
higher
dose
pu
four
subject
flulik
set
symptom
fever
headach
muscl
ach
malais
chill
start
hour
vaccin
last
hour
symptom
moder
sever
subject
nausea
subject
inject
site
pain
discomfort
first
day
vaccin
symptom
improv
treatment
overthecount
medicin
one
subject
histori
intermitt
low
neutrophil
count
neutrophil
count
moder
normal
shortli
studi
vaccin
return
normal
without
symptom
ill
differ
subject
note
persist
grade
alt
start
day
studi
inject
last
month
evalu
diagnos
fatti
liver
steatohepat
clinic
symptom
condit
may
exist
prior
studi
enrol
subject
alcohol
use
recent
weight
gain
may
contribut
factor
one
subject
histori
singl
seizur
three
year
prior
studi
enrol
experienc
seizur
day
studi
inject
subject
diagnosi
epilepsi
anticonvuls
therapi
follow
review
subject
medic
record
given
time
seizur
seizur
assess
unrel
studi
vaccin
subject
mild
temporari
chang
blood
urin
test
unknown
whether
lab
test
chang
diarrhea
fatti
liver
seizur
due
vaccin
factor
combin
preclin
test
rabbit
investig
vaccin
associ
fever
day
inject
decreas
food
consumpt
day
inject
second
inject
inflamm
muscl
around
inject
site
note
includ
tissu
around
capillari
lymphat
near
sciatic
nerv
howev
nerv
damag
note
transient
asymptomat
chang
cholesterol
triglycerid
associ
clinic
patholog
transient
increas
creatin
phosphokinas
cpk
possibl
relat
muscl
inflamm
effect
studi
vaccin
fetu
nurs
babi
unknown
femal
subject
child
bear
potenti
requir
agre
use
birth
control
sexual
intercours
begin
day
prior
enrol
continu
week
women
pregnant
nurs
exclud
studi
either
vaccin
may
caus
posit
hiv
antibodi
test
use
standard
screen
test
posit
indetermin
test
may
neg
employ
social
impact
western
blot
analysi
hiv
pcr
test
done
either
exclud
confirm
hiv
infect
elisa
western
blot
pcr
result
discuss
studi
subject
becom
avail
blood
draw
may
caus
pain
bruis
rare
infect
site
blood
taken
subject
may
believ
vaccin
provid
protect
therefor
practic
riskier
behavior
receiv
extens
counsel
throughout
studi
address
potenti
problem
unknown
benefit
result
studi
particip
other
may
benefit
knowledg
gain
studi
may
aid
develop
hiv
vaccin
copi
protocol
propos
inform
consent
form
written
subject
inform
propos
advertis
materi
submit
irb
written
approv
investig
must
submit
necessari
obtain
approv
irb
subsequ
protocol
amend
chang
inform
consent
document
investig
notifi
irb
deviat
protocol
seriou
advers
event
investig
respons
obtain
irb
approv
annual
continu
review
throughout
durat
studi
divis
aid
niaid
ind
sponsor
protocol
protocol
registr
must
occur
subject
enrol
studi
institut
review
board
irb
must
approv
protocol
consent
form
protocol
must
submit
institut
biosafeti
committe
ibc
approv
letter
irb
ibc
must
initi
protocol
registr
subsequ
protocol
amend
must
also
regist
approv
rcc
protocol
registr
offic
investig
must
ensur
subject
anonym
maintain
subject
identifi
report
studi
record
kept
confidenti
extent
provid
feder
state
local
law
medic
record
made
avail
review
requir
food
drug
administr
author
user
vaccin
manufactur
guidelin
set
feder
privaci
act
direct
access
includ
examin
analyz
verifi
reproduc
record
report
import
evalu
studi
investig
oblig
inform
subject
name
repres
review
studyrel
record
without
violat
confidenti
subject
store
studi
research
sampl
label
code
number
vrc
clinic
team
link
subject
store
research
sampl
log
vrc
laboratori
inform
manag
system
lim
databas
use
sampl
document
lim
requir
maintain
subject
confidenti
includ
studi
inform
consent
document
studi
activ
carri
clinic
center
nation
institut
health
studi
subject
recruit
onsit
offsit
advertis
done
screen
protocol
vrc
effort
made
includ
women
minor
proport
similar
commun
recruit
phase
studi
design
establish
safeti
vaccin
healthi
adult
enrol
limit
person
least
year
age
older
year
age
particip
children
children
elig
particip
clinic
trial
meet
guidelin
inclus
children
research
guidelin
cfr
subpart
state
depart
health
human
servic
protect
children
particip
research
gener
healthi
children
studi
research
consid
greater
minim
risk
children
involv
research
greater
minim
risk
present
prospect
direct
benefit
individu
child
like
yield
generaliz
knowledg
child
disord
condit
subject
compens
time
inconveni
accord
standard
compens
clinic
research
volunt
program
compens
per
visit
visit
includ
inject
blood
draw
visit
includ
blood
draw
inject
visit
includ
inject
site
inspect
photo
includ
remov
skin
biopsi
sutur
need
approxim
total
compens
subject
base
project
clinic
visit
four
inject
week
subject
consent
skin
biopsi
compens
per
skin
biopsi
return
week
longterm
followup
blood
draw
compens
visit
close
cooper
design
member
protocol
team
occur
evalu
respond
individu
advers
event
time
manner
design
team
member
princip
investig
medic
offic
protocol
specialist
studi
coordin
studi
clinician
review
summari
studi
safeti
data
report
weekli
basi
week
last
subject
receiv
third
studi
inject
order
certain
vaccin
accept
safeti
profil
continu
monitor
studi
safeti
data
report
monthli
basi
complet
last
week
visit
daid
medic
offic
provid
independ
review
advers
event
bear
studi
stop
quarterli
safeti
monitor
report
provid
fda
request
confer
call
novemb
see
section
protocol
amend
must
made
prior
approv
nation
institut
allergi
infecti
diseas
divis
aid
vaccin
research
center
agreement
investig
must
obtain
protocol
amend
amend
inform
consent
document
studi
amend
submit
irb
approv
divis
aid
nation
institut
allergi
infecti
diseas
vaccin
research
center
princip
investig
food
drug
administr
reserv
right
termin
studi
investig
notifi
irb
write
studi
complet
earli
termin
investig
maintain
list
appropri
qualifi
person
trial
duti
deleg
sourc
document
origin
document
data
record
subject
data
obtain
includ
limit
hospit
record
clinic
offic
chart
laboratori
pharmaci
record
diari
microfich
radiograph
correspond
investig
staff
respons
maintain
comprehens
central
file
system
studyrel
essenti
document
suitabl
inspect
time
repres
nation
institut
allergi
infecti
diseas
divis
aid
vaccin
research
center
irb
fda
andor
applic
regulatori
author
element
includ
addit
origin
sourc
document
must
maintain
readili
avail
essenti
document
retain
institut
period
time
requir
medic
record
retent
fda
requir
studi
record
retain
two
year
market
approv
refus
cfr
studi
document
destroy
without
prior
written
agreement
nation
institut
allergi
infecti
diseas
divis
aid
vaccin
research
center
investig
investig
wish
assign
studi
record
anoth
parti
move
anoth
locat
must
notifi
nation
institut
allergi
infecti
diseas
divis
aid
vaccin
research
center
write
new
respons
person
andor
new
locat
nation
institut
allergi
infecti
diseas
divis
aid
vaccin
research
center
regulatori
author
inspector
author
repres
respons
contact
visit
investig
purpos
inspect
facil
upon
request
inspect
variou
record
trial
provid
subject
confidenti
respect
site
visit
studi
monitor
made
accord
ind
sponsor
daid
polici
monitor
follow
studi
oper
qualiti
data
collect
research
record
accuraci
timeli
data
enter
databas
determin
process
regulatori
requir
met
site
investig
allow
studi
monitor
niaid
irb
fda
inspect
studi
document
eg
consent
form
drug
distribut
form
case
report
form
pertin
hospit
clinic
record
confirm
studi
data
clinic
research
data
collect
secur
electron
data
manag
system
contract
research
organ
emm
rockvil
md
extract
data
without
patient
identifi
sent
protocol
statistician
statist
analysi
written
inform
materi
use
subject
investig
staff
must
use
vocabulari
languag
clearli
understood
clinic
center
provid
shortterm
medic
care
injuri
result
particip
research
gener
nation
institut
health
clinic
center
feder
govern
provid
longterm
medic
care
financi
compens
researchrel
injuri
invit
take
part
research
studi
nation
institut
health
nih
first
want
know
take
part
nih
research
entir
voluntari
may
choos
take
part
may
withdraw
studi
time
either
case
lose
benefit
otherwis
entitl
howev
receiv
care
nih
must
take
part
studi
evalu
studi
particip
may
receiv
benefit
take
part
research
may
give
us
knowledg
may
help
peopl
futur
second
peopl
person
religi
ethic
belief
may
limit
kind
medic
research
treatment
would
want
receiv
blood
transfus
belief
pleas
discuss
nih
doctor
research
team
agre
studi
describ
research
studi
decid
take
part
pleas
take
much
time
need
ask
question
discuss
studi
anyon
nih
famili
friend
person
physician
health
profession
main
purpos
studi
see
vaccin
schedul
studi
particip
receiv
two
differ
kind
experiment
hiv
vaccin
safe
whether
caus
side
effect
schedul
includ
inject
shot
one
vaccin
inject
anoth
vaccin
call
primeboost
schedul
goal
studi
see
whether
experiment
vaccin
caus
immun
respons
see
inject
first
vaccin
use
needl
syring
similar
safeti
immun
respons
give
inject
needleless
inject
devic
two
experiment
hiv
vaccin
studi
known
call
first
one
dna
vaccin
second
one
rad
vaccin
experiment
vaccin
given
peopl
research
studi
one
first
two
studi
give
vaccin
peopl
primeboost
schedul
experiment
mean
studi
vaccin
approv
food
drug
administr
fda
treat
prevent
hiv
infect
fda
allow
use
research
studi
known
studi
vaccin
prevent
hiv
infect
elig
particip
studi
complet
screen
process
complet
assess
understand
hivneg
year
old
signific
medic
problem
will
donat
blood
sampl
futur
research
forti
peopl
particip
studi
nih
clinic
center
bethesda
maryland
studi
visit
take
week
complet
one
longterm
followup
week
studi
check
vaccin
side
effect
treat
nation
institut
health
side
effect
occur
told
new
inform
learn
studi
might
caus
chang
mind
stay
studi
end
studi
told
studi
result
may
avail
learn
vaccin
substanc
use
tri
creat
immun
respons
bodi
natur
defens
prevent
resist
infect
mani
vaccin
made
protein
inject
muscl
protein
natur
substanc
bodi
use
build
block
live
hiv
viru
studi
vaccin
get
hiv
infect
aid
studi
vaccin
protein
may
made
vaccin
dna
vaccin
first
type
vaccin
get
dna
provid
code
instruct
allow
cell
make
protein
dna
vaccin
made
laboratori
use
synthet
dna
code
part
four
hiv
protein
known
gag
pol
nef
env
dna
instruct
muscl
cell
make
part
hiv
protein
investig
blood
test
see
bodi
immun
respons
vaccin
protein
rad
vaccin
second
type
vaccin
get
modifi
adenoviru
carri
dna
muscl
cell
rad
vaccin
code
part
three
hiv
protein
call
gag
pol
env
manufactur
dna
packag
adenoviru
shell
miss
usual
adenoviru
gene
adenoviru
use
vaccin
chang
reproduc
human
bodi
adenoviru
common
viru
caus
upper
respiratori
infect
common
cold
eye
infect
conjunct
urin
infect
diarrhea
get
adenoviru
infect
rad
vaccin
way
chang
infect
someon
els
studi
vaccin
adenoviru
adenoviru
dna
insert
laboratori
call
vector
adenovir
vector
import
featur
rad
vaccin
adenovir
vector
allow
muscl
cell
make
gag
pol
env
protein
sever
day
mimic
way
immun
system
see
viru
protein
viru
infect
order
creat
adenovir
vector
cultur
deriv
human
fetal
kidney
cell
use
cell
cultur
start
product
rad
vaccin
requir
get
new
fetal
kidney
cell
human
cell
rad
vaccin
inject
nih
includ
member
vaccin
research
center
scientif
staff
develop
investig
vaccin
use
research
studi
result
studi
could
play
role
whether
fda
approv
vaccin
sale
time
futur
approv
futur
sale
vaccin
could
lead
payment
nih
nihvrc
scientist
us
law
govern
scientist
requir
receiv
payment
invent
receiv
money
compens
occur
pleas
discuss
studi
doctor
question
may
issu
studi
receiv
three
inject
milligram
mg
dose
dna
vaccin
inject
shot
given
muscl
upper
arm
may
inject
dna
vaccin
either
needleless
inject
devic
commonli
use
needl
syring
get
one
inject
rad
vaccin
upper
arm
needl
syring
may
get
dose
pu
dose
pu
rad
vaccin
pu
particl
unit
get
pu
rad
vaccin
mean
get
ten
billion
enrol
given
studi
number
studi
subject
studi
enrol
peopl
high
level
adenoviru
antibodi
peopl
low
level
complet
enrol
studi
nurs
enter
adenoviru
antibodi
level
elig
inform
comput
assign
studi
number
studi
start
studi
number
randomli
assign
like
flip
coin
dna
vaccin
inject
devic
rad
vaccin
dose
goe
studi
number
whether
high
low
adenoviru
antibodi
level
equal
chanc
receiv
three
dna
inject
needl
syring
needleless
inject
devic
call
biojector
find
shortli
enrol
whether
needl
syring
biojector
use
three
dna
vaccin
inject
biojector
handheld
system
deliv
vaccin
skin
without
use
needl
system
fda
clearanc
deliv
vaccin
inject
muscl
whether
high
low
adenoviru
antibodi
level
also
equal
chanc
receiv
either
pu
rad
dose
pu
rad
dose
week
neither
studi
staff
know
dose
rad
vaccin
get
week
sever
week
last
person
studi
get
rad
vaccin
studi
staff
told
dose
rad
vaccin
receiv
get
first
vaccin
day
enrol
studi
call
day
inject
given
upper
arm
deltoid
muscl
right
left
arm
altern
time
inject
clinic
staff
observ
least
minut
vaccin
ask
complet
diari
card
home
day
vaccin
requir
record
temperatur
symptom
look
inject
site
day
day
diari
card
must
turn
clinic
first
clinic
visit
occur
day
complet
three
dna
vaccin
must
come
clinic
visit
day
later
instruct
visit
must
either
come
call
clinic
day
vaccin
rad
vaccin
must
call
studi
nurs
one
two
day
vaccin
telephon
call
requir
appoint
contact
studi
nurs
requir
telephon
call
studi
nurs
call
inject
must
come
clinic
seen
rash
hive
fever
higher
substanti
difficulti
daili
activ
go
work
take
care
also
need
come
clinic
problem
nurs
doctor
think
check
exam
blood
test
urin
test
import
follow
instruct
given
clinic
staff
import
know
first
studi
experiment
dna
vaccin
subject
inject
given
inject
small
red
bump
form
follow
scab
scab
form
inject
site
within
week
heal
without
treatment
within
week
photo
taken
arm
dna
vaccin
dna
vaccin
studi
nurs
look
care
arm
followup
visit
nurs
measur
red
swell
look
see
bump
skin
chang
scab
form
nurs
take
photograph
inject
site
inject
site
develop
bump
scab
photo
may
taken
visit
skin
heal
studi
investig
use
photograph
learn
type
vaccin
reaction
may
ask
skin
biopsi
inject
site
bump
scab
form
research
purpos
better
understand
skin
react
dna
vaccin
may
refus
skin
biopsi
ask
two
skin
biopsi
research
purpos
studi
may
skin
biopsi
need
health
care
purpos
skin
biopsi
medic
procedur
remov
small
piec
skin
explain
detail
skin
biopsi
consent
form
skin
biopsi
done
need
sign
separ
consent
skin
biopsi
procedur
day
skin
biopsi
clinic
visit
week
enrol
studi
exact
number
depend
mani
time
clinic
need
see
vaccin
site
four
vaccin
visit
take
hour
complet
clinic
visit
blood
collect
usual
take
hour
visit
may
shorter
visit
check
health
chang
problem
ask
feel
taken
medic
includ
pill
inject
overthecount
medic
herbal
supplement
skin
medic
inhal
form
medic
import
talk
studi
nurs
doctor
get
flu
vaccin
vaccin
studi
studi
staff
help
schedul
vaccin
fit
studi
plan
health
need
met
may
stop
studi
vaccin
get
certain
medicin
get
vaccin
emerg
call
studi
nurs
doctor
start
new
medicin
get
inject
type
urin
sampl
collect
blood
drawn
studi
visit
check
health
told
promptli
test
result
show
health
problem
blood
sampl
use
studi
immun
respons
vaccin
result
immun
respons
test
test
use
check
health
given
studi
amount
blood
drawn
vari
tablespoon
ml
tablespoon
ml
depend
visit
might
also
ask
laboratori
test
regular
visit
need
evalu
chang
health
total
amount
blood
drawn
week
studi
clinic
visit
cup
ml
total
two
cup
ml
drawn
sixweek
period
studi
someon
legal
parent
fact
known
previous
could
troubl
addit
genet
counsel
advic
avail
nation
institut
health
help
understand
natur
implic
genet
find
famili
polici
give
inform
unless
believ
direct
medic
reproduct
implic
famili
agre
particip
studi
waiv
right
may
regard
access
disclosur
record
inform
right
contact
princip
investig
studi
genet
inform
collect
discov
famili
confidenti
result
hla
test
becom
part
medic
record
nih
medic
record
contain
inform
maintain
secur
manner
genet
inform
reveal
other
includ
rel
without
permiss
releas
inform
famili
insur
compani
employ
unless
sign
document
allow
releas
inform
instanc
known
genet
inform
obtain
request
person
appli
health
insur
job
particip
studi
blood
sampl
collect
alreadi
explain
store
sampl
futur
research
learn
hiv
hiv
vaccin
immun
system
andor
medic
condit
result
research
done
store
sampl
given
health
care
provid
put
medic
record
test
result
unlik
routin
medic
test
experiment
preliminari
relev
test
care
unknown
request
howev
result
research
test
discuss
physician
store
sampl
label
code
number
studi
team
link
identifi
inform
kept
confidenti
extent
permit
law
greatest
risk
unplan
releas
inform
medic
record
chanc
inform
given
unauthor
person
without
permiss
small
possibl
problem
unplan
releas
inform
includ
discrimin
appli
insur
employ
similar
problem
may
occur
disclos
inform
agre
medic
record
releas
futur
investig
nih
outsid
nih
may
wish
studi
store
sampl
studi
team
share
materi
may
share
identifi
inform
code
inform
gender
age
health
histori
ethnic
may
also
share
investig
futur
research
studi
use
sampl
review
investig
institut
review
board
irb
special
committe
overse
medic
research
studi
protect
right
welfar
human
subject
volunt
store
materi
use
research
sold
research
done
materi
may
use
develop
new
product
futur
receiv
payment
product
possibl
may
side
effect
inject
receiv
dna
vaccin
two
way
depend
randomli
assign
may
get
inject
standard
way
needl
syring
may
get
inject
needleless
system
call
biojector
needleless
system
use
pressur
carbon
dioxid
instead
needl
inject
vaccin
skin
muscl
differ
kind
needleless
system
use
sinc
deliv
vaccin
type
drug
receiv
rad
vaccin
inject
standard
way
needl
syring
either
type
inject
may
mild
discomfort
may
sting
arm
discomfort
pain
sore
red
swell
symptom
may
last
sever
day
risk
faint
small
chanc
infect
inject
site
ask
record
report
side
effect
may
need
make
extra
visit
clinic
evalu
side
effect
may
use
overthecount
nonprescript
pain
medic
need
possibl
risk
vaccin
gener
includ
fever
chill
rash
ach
pain
nausea
headach
dizzi
fatigu
know
side
effect
occur
vaccin
side
effect
nt
usual
last
long
vaccin
drug
could
immedi
allerg
reaction
includ
rash
hive
even
difficulti
breath
allerg
reaction
life
threaten
therefor
clinic
staff
watch
least
minut
immun
provid
need
treatment
may
side
effect
even
seriou
one
nt
know
yet
therefor
import
report
side
effect
clinic
staff
soon
occur
dna
vaccin
studi
given
peopl
first
studi
peopl
first
studi
start
august
also
vaccin
research
center
studi
nih
risk
side
effect
known
one
person
develop
hive
urticaria
around
time
second
vaccin
inject
hive
kind
allerg
reaction
hive
may
relat
vaccin
allergi
one
person
found
moder
low
blood
sugar
day
vaccin
symptom
differ
person
complain
moder
dizzi
day
th
day
unexpect
find
first
studi
follow
inject
small
red
bump
scab
form
inject
site
scab
less
inch
across
deep
infect
scab
came
day
skin
heal
without
need
treatment
one
person
scab
third
vaccin
first
second
one
person
scab
second
vaccin
first
third
one
person
scab
first
third
vaccin
second
vrc
anoth
studi
similar
dna
vaccin
start
novemb
studi
includ
peopl
got
vaccin
inject
got
placebo
steril
salt
water
inject
laboratori
test
sometim
temporarili
normal
rang
includ
blood
glucos
sugar
liver
test
bilirubin
liver
enzym
red
blood
cell
test
hemoglobin
protein
urin
known
chang
laboratori
test
relat
vaccin
due
caus
pattern
eat
drink
ill
due
daytoday
variat
laboratori
test
result
chang
lab
test
also
seen
peopl
got
placebo
inject
none
temporari
chang
need
treatment
follow
list
condit
possibl
relat
studi
vaccin
one
person
found
low
white
blood
cell
count
day
third
vaccin
person
remain
feel
well
white
blood
cell
count
return
normal
without
treatment
less
week
one
person
develop
skin
rash
second
vaccin
inject
clear
without
treatment
caus
unknown
third
vaccin
inject
given
possibl
risk
relat
dna
vaccin
includ
muscl
damag
antibodi
dna
lead
ill
insert
vaccin
dna
bodi
dna
lead
cancer
dna
bacteria
viru
bodi
none
possibl
risk
dna
vaccin
seen
laboratori
test
anim
human
far
need
awar
possibl
risk
studi
particip
monitor
dna
insert
monitor
clinic
sign
symptom
effect
studi
blood
store
studi
case
addit
safeti
test
need
rad
vaccin
given
peopl
alreadi
receiv
experiment
dna
vaccin
studi
first
rad
booster
studi
start
novemb
site
around
rad
vaccin
peopl
flulik
condit
fever
headach
muscl
ach
tire
feel
chill
start
hour
vaccin
last
hour
peopl
nausea
peopl
inject
site
pain
discomfort
first
day
vaccin
flulik
symptom
inject
site
pain
discomfort
may
treat
overthecount
medicin
pain
fever
follow
list
condit
possibl
relat
studi
vaccin
one
person
white
blood
cell
count
moder
normal
shortli
vaccin
return
normal
without
symptom
ill
one
person
diarrhea
day
shortli
vaccin
one
person
mild
chang
blood
test
liver
function
done
day
vaccin
mild
chang
return
normal
evalu
done
person
found
fatti
liver
condit
may
exist
enrol
studi
person
factor
increas
alcohol
use
recent
weight
gain
may
caus
fatti
liver
one
person
histori
singl
seizur
three
year
enrol
studi
seizur
day
studi
vaccin
seizur
consid
unrel
studi
vaccin
happen
month
vaccin
person
histori
seizur
year
enrol
studi
peopl
mild
temporari
chang
blood
urin
test
known
problem
due
vaccin
due
caus
due
combin
vaccin
caus
anim
toler
vaccin
schedul
dna
vaccin
given
first
follow
rad
vaccin
schedul
rad
vaccin
alon
test
rabbit
schedul
similar
dna
vaccin
follow
rad
vaccin
also
test
rabbit
schedul
rabbit
fever
day
rad
vaccin
inject
rabbit
ate
less
food
usual
day
rad
vaccin
inject
rabbit
inflamm
tissu
near
inject
site
adenovir
vector
adenovir
vector
vaccin
product
given
human
studi
test
treatment
cancer
inherit
condit
one
studi
volunt
die
reaction
adenoviru
vector
given
larg
dose
directli
main
liver
blood
vessel
purpos
treat
inherit
condit
studi
particip
much
lower
dose
use
inject
arm
muscl
studi
regular
blood
test
checkup
perform
check
possibl
side
effect
blood
store
studi
case
addit
safeti
test
need
adenoviru
antibodi
may
develop
antibodi
adenoviru
type
rad
vaccin
possibl
would
abl
receiv
reduc
respons
futur
product
use
adenovir
vector
current
product
approv
fda
use
adenovir
vector
blood
drawn
vein
arm
use
needl
blood
draw
may
caus
pain
bruis
rare
infect
place
blood
taken
sometim
draw
blood
caus
peopl
feel
lighthead
even
faint
counsel
hiv
exposur
studi
question
pleas
ask
clinic
staff
get
experiment
vaccin
studi
may
mean
experiment
hiv
vaccin
studi
later
also
possibl
receiv
experiment
hiv
vaccin
may
alter
respons
futur
hiv
vaccin
may
make
either
less
effect
expos
hiv
sex
drug
use
receiv
studi
inject
risk
becom
hiv
infect
unknown
pleas
anyth
might
expos
hiv
awar
peopl
receiv
experiment
hiv
vaccin
past
becam
infect
hiv
sex
drug
use
know
hiv
infect
aid
develop
even
person
receiv
test
vaccin
hesh
expos
hiv
expos
hiv
sex
drug
use
receiv
studi
vaccin
risk
becom
infect
hiv
develop
aid
unknown
pleas
inform
vrc
clinic
time
think
may
expos
hiv
get
infect
know
effect
studi
vaccin
may
diseas
time
take
becom
sick
hivaid
may
longer
shorter
usual
educ
counsel
hiv
exposur
often
studi
question
pleas
ask
clinic
staff
problem
like
staff
clinic
tri
help
work
blood
test
look
hiv
posit
studi
vaccin
offer
letter
show
join
studi
describ
antibodi
respons
caus
vaccin
even
letter
help
offer
vrc
clinic
may
solv
social
problem
caus
fals
posit
hiv
antibodi
test
also
possibl
other
may
learn
take
part
studi
assum
risk
hiv
infect
sexual
behavior
drug
use
may
result
peopl
treat
differ
know
possibl
effect
studi
vaccin
fetu
nurs
infant
therefor
women
abl
becom
pregnant
must
neg
pregnanc
test
immun
women
must
also
agre
practic
adequ
birth
control
begin
least
day
prior
receiv
first
inject
last
studi
visit
week
abl
children
adequ
method
birth
control
includ
condom
male
femal
without
spermicid
diaphragm
cervic
cap
spermicid
intrauterin
devic
contracept
pill
norplant
depoprovera
male
partner
previous
undergon
vasectomi
document
pregnant
breastfeed
want
becom
pregnant
next
week
particip
must
notifi
clinic
staff
immedi
upon
learn
becom
pregnant
studi
becom
pregnant
receiv
inject
howev
ask
continu
studi
followup
visit
full
week
studi
visit
well
report
outcom
pregnanc
sinc
studi
vaccin
administ
mani
human
safeti
toxic
uncertain
possibl
new
unexpect
side
effect
may
develop
human
observ
anim
test
previou
clinic
trial
made
awar
signific
health
effect
vaccin
seriou
side
effect
occur
volunt
updat
trial
need
studi
may
direct
benefit
one
know
vaccin
hiv
work
howev
other
may
benefit
futur
inform
learn
studi
pay
vaccin
research
clinic
visit
examin
laboratori
test
part
studi
medic
cost
outsid
studi
paid
health
insur
carrier
insur
compens
visit
blood
draw
inject
compens
visit
includ
inject
blood
draw
skin
biopsi
addit
compens
per
biopsi
usual
compens
type
visit
compens
visit
photograph
look
inject
site
includ
remov
skin
biopsi
stitch
need
approxim
total
compens
week
studi
without
skin
biopsi
actual
compens
base
number
studi
visit
attend
number
studi
inject
receiv
skin
biopsi
paid
throughout
studi
reimburs
visit
blood
drawn
week
compens
extra
longterm
visit
may
ask
leav
studi
sever
differ
reason
includ
nt
keep
appoint
follow
studi
procedur
studi
sponsor
studi
doctor
decid
stop
cancel
studi
invit
take
part
research
studi
nation
institut
health
nih
first
want
know
take
part
nih
research
entir
voluntari
may
choos
take
part
may
withdraw
studi
time
either
case
lose
benefit
otherwis
entitl
howev
receiv
care
nih
must
take
part
studi
evalu
studi
particip
may
receiv
benefit
take
part
research
may
give
us
knowledg
may
help
peopl
futur
second
peopl
person
religi
ethic
belief
may
limit
kind
medic
research
treatment
would
want
receiv
blood
transfus
belief
pleas
discuss
nih
doctor
research
team
agre
studi
describ
research
studi
decid
take
part
pleas
take
much
time
need
ask
question
discuss
studi
anyon
nih
famili
friend
person
physician
health
profession
particip
studi
two
experiment
hiv
vaccin
vaccin
known
call
first
one
dna
vaccin
second
one
rad
vaccin
dna
vaccin
sometim
caus
red
bump
arm
vaccin
site
form
scab
day
consent
offer
choic
skin
biopsi
skin
biopsi
dna
vaccin
site
skin
biopsi
research
purpos
better
understand
skin
react
dna
vaccin
skin
biopsi
medic
procedur
skin
biopsi
remov
small
piec
skin
purpos
look
skin
microscop
separ
consent
skin
biopsi
need
two
reason
first
may
choos
skin
biopsi
second
understand
way
skin
biopsi
done
risk
skin
biopsi
decid
whether
one
elig
skin
biopsi
recent
vaccin
vrc
studi
mani
forti
peopl
receiv
vaccin
vrc
studi
peopl
may
two
skin
biopsi
may
one
skin
biopsi
may
skin
biopsi
would
unusu
anyon
two
biopsi
studi
howev
two
skin
biopsi
may
recommend
need
clinic
care
purpos
skin
biopsi
done
nation
institut
health
clinic
center
also
treat
side
effect
skin
biopsi
occur
told
new
inform
learn
studi
might
caus
chang
mind
skin
biopsi
skin
biopsi
report
given
wish
copi
skin
biopsi
done
outpati
clinic
receiv
medicin
lidocain
epinephrin
upper
arm
reduc
pain
call
anesthet
anesthet
may
given
inject
appli
skin
anesthet
may
sting
briefli
ever
allerg
reaction
numb
medicin
novocain
lidocain
commonli
use
dentist
surgeon
sign
consent
detail
allerg
reaction
discuss
studi
doctor
skin
numb
sharp
hollow
instrument
use
remov
small
circular
piec
skin
circl
size
pencil
eras
biopsi
method
call
punch
biopsi
punch
biopsi
skin
may
close
one
two
stitch
must
follow
direct
given
keep
area
clean
heal
must
return
clinic
appoint
given
stitch
remov
sever
day
later
care
method
clean
equip
use
prevent
infect
microscop
slide
made
laboratori
piec
skin
slide
may
differ
stain
test
done
understand
skin
reaction
studi
vaccin
slide
photo
slide
may
kept
record
skin
biopsi
nih
clinic
center
skin
biopsi
sampl
slide
made
label
name
part
medic
record
hospit
laboratori
record
photo
slide
use
report
studi
result
identifi
number
code
label
name
result
skin
biopsi
photo
slide
record
studi
record
label
studi
identif
number
time
skin
open
chanc
infect
infect
skin
biopsi
rare
care
taken
tri
prevent
infect
may
pain
discomfort
skin
biopsi
heal
may
small
amount
bleed
right
skin
biopsi
may
small
scar
skin
tend
form
larg
scar
type
call
keloid
risk
keloid
form
biopsi
area
histori
keloid
format
increas
risk
keloid
scar
skin
biopsi
known
histori
keloid
scar
advis
inform
studi
staff
skin
biopsi
research
purpos
rare
anesthet
medicin
use
numb
skin
may
caus
allerg
reaction
anesthet
may
also
interact
certain
medicin
caus
seriou
side
effect
sure
review
medic
drug
use
studi
staff
agre
local
anesthet
certain
antidepress
medicin
illicit
drug
cocain
among
drug
react
anesthet
caus
side
effect
may
benefit
skin
biopsi
skin
medic
condit
may
learn
caus
problem
charg
health
insur
compani
skin
biopsi
care
skin
biopsi
howev
cost
medic
care
period
charg
insur
compani
paid
usual
compens
visit
includ
skin
biopsi
skin
biopsi
stitch
remov
day
later
one
visit
describ
studi
consent
includ
photograph
compens
photo
visit
whether
stitch
also
need
remov
time
may
choos
skin
biopsi
